Rec'd PCT/PTO 0 8 OCT 2004

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

10/510912

(19) World Intellectual Property Organization
International Bureau

PCT

(71) Applicant (for all designated States except US): MERCK & CO., INC. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065-0907 (US).

(72) Inventors; and
(75) Inventors/Applicants (for US only): FLORES, Osvaldo, A. [CL/US]; 126 East Lincoln Avenue, Rahway, NJ 07065-0907 (US). GROBLER, Jay [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065-0907 (US). MURRAY, Edward, M. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065-0907 (US). ZUCK, Paul, D. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065-0907 (US).

(74) Common Representative: MERCK & CO., INC.; 126 East Lincoln Avenue, Rahway, NJ 07065-0907 (US).

(54) Title: HEPATITIS C VIRUS ASSAY SYSTEMS

(57) Abstract: The present invention features assays employing a beta-lactamase reporter system, an HCV replicon enhanced cell, and/or a chimeric HCV replicon containing a 3' UTR based on the HCV-1a 3' UTR. These features can be employed alone or together, and are preferably combined together to measure HCV replicon activity and the affect of compounds on such activity

WO 03/089672 A1

TITLE OF THE INVENTION
HEPATITIS C VIRUS ASSAY SYSTEMS

CROSS-REFERENCE TO RELATED APPLICATIONS

5   The present application claims priority to provisional application U.S. Serial No. 60/372,847, filed April 16, 2002, hereby incorporated by reference herein.

BACKGROUND OF THE INVENTION

     The references cited in the present application are not admitted to be

10   prior art to the claimed invention.

     It is estimated that about 3% of the world's population are infected with the Hepatitis C virus (HCV). (Wasley, *et al.*, 2000. *Semin. Liver Dis. 20*, 1-16.) Exposure to HCV results in an overt acute disease in a small percentage of cases, while in most instances the virus establishes a chronic infection causing liver

15   inflammation and slowly progresses into liver failure and cirrhosis. (Iwarson, 1994. *FEMS Microbiol. Rev. 14*, 201-204.) In addition, epidemiological surveys indicate an important role of HCV in the pathogenesis of hepatocellular carcinoma. (Kew, 1994. *FEMS Microbiol. Rev. 14*, 211-220, Alter, 1995. *Blood 85*, 1681-1695.)

     The HCV genome consists of a single strand RNA of about 9.5 kb in

20   length, encoding a precursor polyprotein of about 3000 amino acids. (Choo, *et al.*, 1989. *Science 244*, 362-364, Choo, *et al.*, 1989. *Science 244*, 359-362, Takamizawa, *et al.*, 1991. *J. Virol. 65*, 1105-1113.) The HCV polyprotein contains the viral proteins in the order: C-E1-E2-p7-NS2-NS3-NS4A-NS4B-NS5A-NS5B.

     Individual viral proteins are produced by proteolysis of the HCV

25   polyprotein. Host cell proteases release the putative structural proteins C, E1, E2, and p7, and create the N-terminus of NS2 at amino acid 810. (Mizushima, *et al.*, 1994. *J. Virol. 68*, 2731-2734, Hijikata, *et al.*, 1993. *P.N.A.S. USA 90*, 10773-10777.)

     The non-structural proteins NS3, NS4A, NS4B, NS5A and NS5B presumably form the virus replication machinery and are released from the

30   polyprotein. A zinc-dependent protease associated with NS2 and the N-terminus of NS3 is responsible for cleavage between NS2 and NS3. (Grakoui, *et al.*, 1993. *J. Virol. 67*, 1385-1395, Hijikata, *et al.*, 1993. *P.N.A.S. USA 90*, 10773-10777.)

     A distinct serine protease located in the N-terminal domain of NS3 is responsible for proteolytic cleavages at the NS3/NS4A, NS4A/NS4B, NS4B/NS5A

35   and NS5A/NS5B junctions. (Barthenschlager, *et al.*, 1993. *J. Virol. 67*, 3835-3844,

Grakoui, *et al.*, 1993. *Proc. Natl. Acad. Sci. USA 90*, 10583-10587, Tomei, *et al.*, 1993. *J. Virol. 67*, 4017-4026.) RNA stimulated NTPase and helicase activities are located in the C-terminal domain of NS3.

NS4A provides a cofactor for NS3 protease activity. (Failla, *et al., J. Virol.* 1994. *68*, 3753-3760, De Francesco, *et al.*, U.S. Patent No. 5,739,002.)

NS5A is a highly phosphorylated protein conferring interferon resistance. (De Francesco, *et al.*, 2000. *Semin Liver Dis.*, *20*(1), 69-83, Pawlotsky, 1999. *J. Viral Hepat. Suppl. 1*, 47-48.)

NS5B provides an RNA-dependent RNA polymerase. (De Francesco, *et al.*, International Publication Number WO 96/37619, Behrens, *et al.*, 1996. *EMBO 15*, 12-22, Lohmann, *et al.*, 1998. *Virology 249*, 108-118.)

SUMMARY OF THE INVENTION

The present invention features assays employing a beta-lactamase reporter system, an HCV replicon enhanced cell, and/or a chimeric HCV replicon containing a 3'UTR based on the HCV-1a 3' UTR. These features can be employed alone or together, and are preferably combined together to measure HCV replicon activity and the affect of compounds on such activity.

Thus, a first aspect of the present invention describes a method of measuring the ability of a compound to alter HCV replicon activity using a screening cell line comprising a first HCV replicon and a second HCV replicon. The first replicon comprises a selection sequence. The second replicon comprises a nucleotide sequence encoding for beta-lactamase. The method is performed using conditions supporting beta-lactamase activity. Such conditions provide the proper environment for beta-lactamase activity and include factors such as proper pH, temperature and buffer.

A selection sequence facilitates identification or isolation of cells containing the sequence. Examples of selection sequences include sequences encoding drug resistance and reporters compatible with cell sorting.

Another aspect of the present invention describes an HCV replicon enhanced cell comprising a first HCV replicon and a second HCV replicon. The first replicon comprises a selection sequence and is present in an amount compatible with replication of the second replicon. The second replicon is different from the first replicon and preferably encodes a reporter.

Another aspect of the present invention describes a method of producing an HCV replicon enhanced cell. The method comprises the steps of: (a) introducing into a cell a HCV replicon comprising a selection sequence; (b) obtaining a replicon enhanced cell; and (c) introducing into the replicon enhanced cell a replicon

5   comprising a reporter.

Another aspect of the present invention describes an HCV replicon comprising a beta-lactamase reporter. In this aspect, the replicon does not contain a sequence coding for resistance to an agent that inhibits cell growth.

Another aspect of the present invention describes a chimeric HCV

10 replicon containing an HCV-1a 3' UTR. The chimeric replicon contains one or more HCV regions from different HCV strains. Reference to strains includes subtypes, which may be clinical isolates. Examples of chimeric replicons include replicons formed from one or more strains classified as HCV-1a, where the replicon contains a 3' UTR from one strain and one or more HCV regions from a different strain(s); and

15 the replicon being formed from two or more HCV strains classified in different groups, where the replicon contains a 3' HCV-1a UTR.

Preferably, the chimeric replicon contains the HCV-1a 3'UTR provided by bases 8407-8641 of SEQ. ID. NO. 1. The remainder of such a chimeric replicon contains one or more HCV regions, preferably a non-structural region, from a

20 HCV strain not containing the HCV-1a 3' UTR provided by SEQ. ID. NO. 1.

Other features and advantages of the present invention are apparent from the additional descriptions provided herein including the different examples. The provided examples illustrate different components and methodology useful in practicing the present invention. The examples do not limit the claimed invention.

25 Based on the present disclosure the skilled artisan can identify and employ other components and methodology useful for practicing the present invention.

BRIEF DESCRIPTION OF THE DRAWINGS

Figures 1A-1D illustrate the HCV replicon of SEQ. ID. NO. 1.

30 Sequences of all non-structural proteins are derived from con1. The approximate location of different regions of SEQ. ID. NO. 1 are as follows:

1-341: 5'-nontranslated region

342-1178: HCV core – β-lactamase fusion protein

1225-1800: EMCV IRES

35 1801-2451: NS2

2452-4344: NS3

4345-4506: NS4A

4507-5289: NS4B

5290-6630: NS5A

5 6631-8406: NS5B

8407-8641: HCV(1a) 3'-nontranslated region

8642-8732: Hepatitis delta ribozyme.

   Figures 2A-2D illustrate the HCV replicon of SEQ. ID. NO. 2.

Sequences of all non-structural proteins are derived from con1. The approximate

10 location of different regions of SEQ. ID. NO. 2 are as follows:

1-341: 5'-nontranslated region

342-1178: HCV core – β-lactamase fusion protein

1225-1800: EMCV IRES

1801-3696: NS3

15 3697-3858: NS4A

3859-4641: NS4B

4642-5982: NS5A

5983-7755: NS5B

5991-5996: BstZ17I restriction site

20 7751-7756: Cla I restriction site

7756-7993: HCV(1a) 3'-nontranslated region

7994-8085: Hepatitis delta ribozyme.

   Figures 3A and 3B provide schematic diagrams of replicons of SEQ.

ID. NO. 1 and SEQ. ID. NO. 2. Both replicons are derived from HCV con1 and

25 contain the S2204I adaptive mutation in NS5A. An HCV genotype 1a 3'-UTR is

present in both clones, and both have a hepatitis delta ribozyme that is autocleaved to

yield native 3'-ends. (A) Structure of the replicon SEQ. ID. NO.1 which encodes NS2

through NS5B. (B) Structure of replicon SEQ. ID. NO. 2. which encodes NS3

through NS5B. The replicon of SEQ. ID. NO. 2 contains unique BstZ17 I and Cla I

30 restriction sites at the 5' and 3' ends of the NS5B coding region, respectively, to

facilitate subcloning of NS5B sequences for resistance phenotyping.

   Figure 4 illustrates quantitation of replicon RNA in different cell lines.

Replicon RNA was quantitated using strand specific RNAse protection assays.

Cellular GAPDH RNA and HCV replicon RNA of positive polarity are shown at the

top and lower panels respectively. The ratios of positive to negative strand replicon RNA in each cell line are indicated at the bottom of the figure.

Figure 5 illustrates stable maintenance of replicons harboring different adaptive mutations in partially cured JGEM cells.

5   Figure 6 illustrates persistence of beta-lactamase activity in the presence of inhibitor. The decay rates of beta-lactamase activity was measured in the presence of an NS5B inhibitor at 100% inhibitory dose (open symbols) either with (circles) or without (triangles) 0.5 μM clavulanic acid. Closed symbols represent cells without NS5B inhibitor.

10

DETAILED DESCRIPTION OF THE INVENTION

The present invention features assays employing a beta-lactamase reporter system, an HCV replicon enhanced cell, and/or a chimeric HCV replicon containing a HCV-1a 3' UTR. These different features are preferably employed

15   together to evaluate the ability of a compound to inhibit HCV replication.

Compounds inhibiting HCV replication have research and therapeutic applications. Research applications include the study of HCV and the production of replicon enhanced cells. Therapeutic applications include using those compounds having appropriate pharmacological properties such as efficacy and lack of

20   unacceptable toxicity to treat or inhibit onset of HCV in a patient.

I. Beta-Lactamase Reporter Systems

Assays employing a beta-lactamase reporter system can be used to measure the activity of a nucleic acid or polypeptide coupled to a beta-lactamase and

25   the effect of a compound on such activity. Nucleic acid coupled to a beta-lactamase contains a target nucleotide region and a region encoding a beta-lactamase. Beta-lactamase is the byproduct of target nucleic acid expression and measuring Bla activity provides a mean to measure target nucleic acid activity.

The target nucleotide region is a region of interest and can provide

30   regulatory activities or encode for a polypeptide. Reference to polypeptide and polypeptide region does not provide a size limitation and includes smaller length polypeptides, enzymatic proteins, structural proteins, and polyproteins.

Activities that can be measured using a target nucleotide region and a region encoding a beta-lactamase include one or more of the following: target

35   nucleotide region production, target nucleotide region processing, target nucleotide

region transport, activity of encoded for polypeptides involved in replication, and production of encoded for polypeptides. Nucleotide region transport includes extracellular transport that may be viral mediated.

5   A polypeptide coupled to beta-lactamase is a chimeric polypeptide containing a region of interest and a beta-lactamase. Polypeptide regions of interest include those providing enzymatic and structural proteins.

Polypeptide activities that can be measured using a beta-lactamase reporter system include one or more of the following: polypeptide production, polypeptide processing and polypeptide transport. Polypeptide transport includes

10   extracellular transport that may be viral mediated.

A preferred target nucleic acid is an HCV replicon. HCV replicons containing a region encoding a beta-lactamase can be used to measure the effect of a compound on both HCV nucleic acid and HCV protein activity. HCV proteins are involved in processing the HCV polyprotein and in HCV replication. Inhibiting HCV

15   proteins involved in HCV processing or more directly involved in HCV replication reduces the production of HCV replicons encoding beta-lactamase.

II. Beta-Lactamase Activity

Beta-lactamases are enzymes catalyzing the cleavage of the beta-

20   lactam ring present in cephalosporins. Different naturally occurring beta-lactamases and functionally derivatives of naturally occurring beta-lactamases are well known in the art. References such as Ambler, *Phil. Trans R. Soc. Lond. Ser.* B. *289*:321-331, 1980, provide examples of naturally occurring ß-lactamases.

Beta-lactamases that are functional derivatives of a naturally occurring

25   beta-lactamase can be produced by altering a naturally occurring sequence to produce an enzyme retaining beta-lactamase activity. Examples of common alterations include substitutions, deletions, and additions of amino acids or amino acid regions.

One method of designing altered proteins is to take into account amino acid R-groups. An amino acid R group affects different properties of the amino acid

30   such as physical size, charge, and hydrophobicity. Amino acids can be divided into different groups as follows: neutral and hydrophobic (alanine, valine, leucine, isoleucine, proline, tryptophan, phenylalanine, and methionine); neutral and polar (glycine, serine, threonine, tyrosine, cysteine, asparagine, and glutamine); basic (lysine, arginine, and histidine); and acidic (aspartic acid and glutamic acid).

Generally, in substituting different amino acids it is preferable to exchange amino acids having similar properties. Substituting different amino acids within a particular group, such as substituting valine for leucine, arginine for lysine, and asparagine for glutamine are good candidates for not causing a change in
5   polypeptide functioning.

Changes outside of different amino acid groups can also be made. Preferably, such changes are made taking into account the position of the amino acid to be substituted in the polypeptide. For example, arginine can substitute more freely for nonpolar amino acids in the interior of a polypeptide than glutamate because of its
10   long aliphatic side chain. (*See*, Ausubel, *Current Protocols in Molecular Biology*, John Wiley, 1987-1998, Supplement 33 Appendix 1C.)

Derivatives can be produced to enhance intracellular activity. An example of such a derivative is TEM-1 beta-lactamase. (Kadonaga *et al., J. Biol. Chem. 259*:2149-2154, 1984.) TEM-1 beta-lactamase is a derivative of *E. coli* beta-
15   lactamase where the signal sequence is deleted. The deletion of the signal sequence increases cytoplasmic accumulation.

Beta-lactamase encoding sequences can be incorporated into nucleic acids taking into account the genetic code. The translation of a particular codon into a particular amino acid is well known in the art (*see, e.g.*, Lewin *GENES IV*, p. 119,
20   Oxford University Press, 1990). Amino acids are encoded by codons as follows:

A=Ala=Alanine: codons GCA, GCC, GCG, GCU

C=Cys=Cysteine: codons UGC, UGU

D=Asp=Aspartic acid: codons GAC, GAU

E=Glu=Glutamic acid: codons GAA, GAG

25   F=Phe=Phenylalanine: codons UUC, UUU

G=Gly=Glycine: codons GGA, GGC, GGG, GGU

H=His=Histidine: codons CAC, CAU

I=Ile=Isoleucine: codons AUA, AUC, AUU

K=Lys=Lysine: codons AAA, AAG

30   L=Leu=Leucine: codons UUA, UUG, CUA, CUC, CUG, CUU

M=Met=Methionine: codon AUG

N=Asn=Asparagine: codons AAC, AAU

P=Pro=Proline: codons CCA, CCC, CCG, CCU

Q=Gln=Glutamine: codons CAA, CAG

35   R=Arg=Arginine: codons AGA, AGG, CGA, CGC, CGG, CGU

S=Ser=Serine: codons AGC, AGU, UCA, UCC, UCG, UCU

T=Thr=Threonine: codons ACA, ACC, ACG, ACU

V=Val=Valine: codons GUA, GUC, GUG, GUU

W=Trp=Tryptophan: codon UGG

5   Y=Tyr=Tyrosine: codons UAC, UAU.

III. Beta-Lactamase Assays

Intracellular beta-lactamase activity is preferably measured using a
fluorogenic substrate that is cleaved by beta-lactamase. Preferred substrates are
10   membrane permeant fluorogenic substrates that become membrane impermeant inside
a cell, and that are cleaved by beta-lactamase to produce a detectable signal.
Examples of such substrates are provided in Zlokarnik, *et al.,* 1998. *Science 279*:84-
88, and Tsien *et al.,* U.S. Patent No. 5,741,657.

In an embodiment of the present invention, a cell-permeant fluorescent
15   β-lactamase substrate such as CCF2-AM or CCF4-AM (Aurora Biosciences, Inc., San
Diego, CA) is loaded into a cell. These substrates contain an ester group facilitating
transport across the cell membrane. Inside the cell, the ester group is cleaved
rendering the substrate membrane impermeant. The intact substrates when stimulated
with light of ~405 nm, emit green fluorescence (~530 nm) due to resonant energy
20   transfer from a coumarin to fluorescein dye molecule. Cleavage of the substrate by
beta-lactamase disrupts the resonance energy transfer and, the fluorescence emission
changes to a blue color (~460 nm) of only the coumarin. The fluorescence emissions
of the substrate present in the cells can be detected by, for example, fluorescence
microscopy or by a fluorometer in conjunction with appropriate emission and
25   excitation filters.

IV. Use Of Beta-Lactamase Inhibitor

Beta-lactamase inhibitors such as clavulanic acid can be used to
enhance a beta-lactamase reporter system by being present throughout the assay. For
30   example, clavulanic acid being present throughout an assay involving an HCV
replicon beta-lactamase reporter sensitizes the assay towards HCV replication
inhibitors.

Clavulanic acid can be used to enhance the signal-to-background ratio
from the beta-lactamase reporter system wherein, a larger signal to noise ratio
35   facilitates detection of HCV replication inhibitors by better reflecting changes in the

intracellular concentration of beta-lactamase. Because clavulanic acid is an irreversible inhibitor, it is a more potent inhibitor of beta-lactamase at low enzyme concentrations than at high enzyme concentrations and therefore its inhibitory activity has a more pronounced effect in the background signal than in the foreground signal

5   of the assay.

In different embodiments concerning the level of signal-to-background reduction, the beta-lactamase inhibitor is provided in an amount sufficient to enhance the signal-to-background ratio by 2 to 5 fold; the amount of inhibitor is about 10 nM to 1.0 μM; and/or the inhibitor is an irreversible inhibitor, preferably clavulanic acid.

10

V. HCV Replicons

An HCV replicon is an RNA molecule able to autonomously replicate in a cultured cell and produce detectable levels of one or more HCV proteins. The HCV replicon expresses the HCV derived components of the replication machinery

15   and contains cis-elements required for replication in a cultured cell.

The production and use of HCV replicons, and the effect of different mutations on replicon activity are described in different references. (See, for example, Lohmann, *et al.*, 1999. *Science 285*, 110-113, Bartenschlager, European Patent Application 1 043 399, published October 11, 2000, Blight, *et al.*, 2000.

20   *Science 290*:1972-1974, Lohmann, *et al.*, 2001. *Journal of Virology 75*:1437-1449, and Pietschmann, *et al.*, 2001. *Journal of Virology 75*:1252-1264.)

The basic subunit of an HCV replicon encodes for a HCV NS3-NS4A-NS4B-NS5A-NS5B polyprotein (also referred to as NS3-NS5B) along with a suitable 5'-UTR-partial core (PC) region and 3' UTR. NS3-NS5B may contain different

25   regions from different HCV strains. The 5'-UTR-PC region is made up of a 5'-UTR region and about 36 nucleotides of the beginning of the core. Additional regions may be present including those coding for HCV proteins or elements such as the complete core, E1, E2, p7 or NS2; and those coding for other types of proteins or elements such as a encephalomyocarditis virus (EMCV) internal ribosome entry site (IRES), a

30   reporter protein, or a selection protein.

The HCV 5'-UTR-PC region provides an IRES for protein translation and elements needed for replication. The HCV 5'-UTR-PC region includes naturally occurring HCV 5'UTR extending about 36 nucleotides into a HCV core encoding region, and functional derivatives thereof. The IRES and PC can be present in

different locations such as site downstream from a sequence encoding a selection protein, a reporter, protein, or an HCV polyprotein.

Functional derivatives of the 5'-UTR-PC region able to initiate translation and assist replication can be designed taking into account structural requirements for HCV translation initiation. (See, for example, Honda, *et al.*, 1996. *Virology 222*, 31-42). The effect of different modifications to a 5' UTR-PC region can be determined using techniques measuring replicon activity.

In addition to the HCV 5' UTR-PC region, other types of IRES elements can also be present in the replicon. The other types of IRES elements can be present in different locations including immediately upstream the region encoding an HCV polyprotein. Examples of non-HCV IRES elements that can be used are the EMCV IRES, poliovirus IRES, and bovine viral diarrhea virus IRES.

The HCV 3' UTR assists HCV replication. HCV 3' UTR includes naturally occurring HCV 3' UTR and functional derivatives thereof. Naturally occurring 3' UTR's include a poly U tract and an additional region of about 100 nucleotides. (Tanaka, *et al.*, 1996. *J. Virol. 70*, 3307-3312, Kolykhalov, *et al.*, 1996. *J. Virol. 70*, 3363-3371.) At least *in vivo*, the 3' UTR appears to be essential for replication. (Kolykhalov, *et al.*, 2000. *J. Virol. 4*, 2046-2051.) Examples of naturally occurring 3' UTR derivatives are described by Bartenschlager International Publication Number EP 1 043 399.

The NS3-NS5B polyprotein encoding region provides for a polyprotein that can be processed in a cell into different proteins. Suitable NS3-NS5B polyprotein sequences that may be part of a replicon include those present in different HCV strains and functional equivalents thereof resulting in the processing of NS3-NS5B to produce functional replication machinery. Proper processing can be measured by assaying, for example, HCV protein production.

An HCV replicon may contain non-HCV sequences in addition to HCV sequences. The additional sequences should not prevent replication and expression, and preferably serve a useful function. Sequences that can be used to serve a useful function include a selection sequence, a reporter sequence, transcription elements and translation elements.

A selection sequence in an HCV replicon facilitates the identification and/or isolation of a cell containing the replicon. Selection sequences providing for resistance to an agent that inhibits cell growth can be used in conjunction with some selective pressure that inhibits growth of cells not containing the selection sequence.

Examples of selection sequences include sequences encoding for antibiotic resistance, and ribozymes; and reporters compatible with cell sorting such as green fluorescence protein and beta-lactamase.

Antibiotic resistance can be used in conjunction with an antibiotic to
5   select for cells containing replicons. Examples of selection sequences providing for antibiotic resistance are sequences encoding resistance to neomycin, hygromycin, puromycin, or zeocin.

A ribozyme serving as a selection sequence can be used in conjunction with an inhibitory nucleic acid molecule that prevents cellular growth. The ribozyme
10   recognizes and cleaves the inhibitory nucleic acid.

A reporter sequence can be used to detect replicon replication or protein expression. Preferred reporter proteins are enzymatic proteins whose presence can be detected by measuring product produced by the protein. Examples of reporter proteins include luciferase, beta-lactamase, secretory alkaline phosphatase, beta-
15   glucuronidase, green fluorescent protein and its derivatives. In addition, a reporter nucleic acid sequence can be used to provide a reference sequence that can be targeted by a complementary nucleic acid. Hybridization of the complementary nucleic acid to its target can be determined using standard techniques.

Replicons containing reporter sequences may or may not also contain a
20   selection sequence. Selection sequences providing resistance to an agent that inhibits cell growth can be used in conjunction with selective pressure to select for cells maintaining the replicon. The Examples provides below illustrate that replicons containing a beta-lactamase reporter sequences are sufficiently maintained in the absence of selective pressure. In an embodiment of the present invention the replicon
25   contains a reporter sequence (preferably, beta-lactamase), and does not contain a sequence coding for resistance to an agent that inhibits cell growth.

Additional sequences can be part of the same cistron as the HCV polyprotein or can be a separate cistron. If part of the same cistron, additional sequences coding for a protein should result in a product that is either active as a
30   chimeric protein or is cleaved inside a cell so it is separated from HCV protein.

Selection and reporter sequences encoding a protein when present as a separate cistron should be associated with elements needed for translation. Such elements include an IRES 5' to the selection or reporter sequence.

A preferred construct is a bicistronic replicon, where one cistron
35   encodes for a selection or reporter sequence and the second cistron encodes for HCV

11

proteins. More preferably, the first cistron contain a HCV 5'-UTR-PC region joined
to the selection or reporter sequence; and the second cistron contains the EMCV
internal ribosome entry site, NS2-NS5B or NS3-NS5B, and a 3' UTR. Examples of
bicistronic constructs are illustrated by SEQ. ID. NOs. 1 and 2.

5   Preferred cells for use with a HCV replicon are Huh-7 cells and Huh-7
derived cells. "Huh-7 derived cells" are cells produced starting with Huh-7 cells and
introducing one or more phenotypic and/or genotypic modifications.

VI. HCV Replicon Sequences

10   HCV sequences for use in HCV replicons include HCV sequences
present in different HCV strains and functional derivatives thereof. Functional
derivatives can process the HCV polyprotein and provide for HCV replication.

Replicon activity from naturally occurring sequences providing for
little or no detectable replicon activity in a cell can be enhanced by producing
15   functional derivatives containing adaptive mutations. Adaptive mutations and
techniques for selecting for adaptive mutations are well known in the art. (See, for
example, Lohmann, *et al.,* 1999. *Science 285*, 110-113, Bartenschlager, European
Patent Application 1 043 399, published October 11, 2000, Blight, *et al.,* 2000.
Science 290:1972-1974, Lohmann, *et al.,* 2001. *Journal of Virology 75*:1437-1449,
20   and Pietschmann, *et al.,* 2001. *Journal of Virology 75*:1252-1264, 2001.)

Numerous examples of naturally occurring HCV isolates are well
known in the art. HCV isolates can be classified into the following six major
genotypes comprising one or more subtypes: HCV-1/(1a, 1b, 1c), HCV-2/(2a, 2b, 2c),
HCV-3/(3a, 3b, 10a), HCV-4/(4a), HCV-5/(5a) and HCV-6/(6a, 6b, 7b, 8b, 9a, 11a).
25   (Simmonds, 2001. *J. Gen. Virol., 82*, 693-712.) Examples of HCV sequences have
been deposited in GenBank and described in various publications. (See, for example,
Chamberlain, *et al.,* 1997. *J. Gen. Virol., 78*, 1341-1347)

VII. Chimeric HCV Replicons and Resistance Phenotyping

30   Chimeric HCV replicons contain HCV regions from different HCV
strains and can be used, for example, to measure the effect of a compound on HCV
activity and to provide a template for HCV resistance phenotyping. The starting
template for HCV resistance phenotyping is a functional replicon. One or more

different regions of the functional replicon can be replaced with an HCV region from a different strain, including HCV obtained from a patient infected with the virus.

The template used for HCV resistance phenotying can contain regions from different HCV strains. Preferably, the template contains a HCV-1a 3' UTR.

5   Bases 8407-8641 of SEQ. ID. NO. 1 provide the nucleotide sequence of the HCV-1a 3' UTR.

HCV resistance phenotyping can be performed by examining the sensitivity of different HCV targets isolated from a clinical sample to experimental or approved HCV drugs using a chimeric replicon. HCV targets that can be analyzed

10   include HCV encoded enzymes such as NS2/3 protease, NS3 protease, NS3 helicase, and NS5B, as well as polynucleotide regions important for HCV replication. In different embodiments concerning HCV chimeric replicons, the replicon comprises:

a) a HCV 3'UTR, preferably HCV-1a UTR,

b) HCV non structural proteins from any one genotype or any

15   combination of genotypes as long as the combination supports HCV replication, different HCV genotypes include HCV-1, HCV-2, HCV-3, HCV-4, HCV-5, and HCV-6; preferably, the non-structural regions contain one region from a clinical isolate;

c) restriction sites that are silent with respect to coding that facilitate

20   introduction of HCV sequences obtained from a clinical isolate; and

d) a reporter gene, preferably beta-lactamase.

Resistance phenotyping can be performed by isolating an HCV target region from a clinical isolate, and transferring the region to a template replicon. An example of a procedure for constructing a chimeric HCV replicon for use in resistance

25   phenotyping is as follows:

a) Isolation and purification: isolation and purification of HCV genomic RNAs from infected patient serum can be achieved using well known techniques. (Examples of such techniques are described in Chamberlain, *et. al.*, 1997. *J. Gen. Virol.*, *78*, 1341-1347, Grahovac, *et. al.*, 2001. *J. Clin. Virol. 20*, 85-89,

30   Castelain, *et al.*, 2002. *JID 185*, 573-583, Farci, *et. al.*, 2002. *PNAS 99*, 3081-3086.)

b) Reverse transcription of HCV RNA and PCR amplification of HCV DNA: Oligonucleotide primers specific to the highly conserved 3'-end of the 3'-non-translated regions can be used to generate cDNA copies of genomic RNA;

c) Amplification of desired target sequences. Polymerase chain

35   reaction amplification can performed to amplify the target sequence using primers 5'

13

and 3' of the target sequence. The primers preferably contain restriction sites that facilitate cloning. Examples of useful restriction sites include BstZ17 I and Cla I and Bcl I; and

      d) Subcloning of target sequence: Restriction enzymes are used to
5   subclone the target sequence into a HCV replicon.

      Two examples of HCV template sequences useful for resistance phenotyping are provided by SEQ. ID. NO. 1 and SEQ. ID. NO. 2. SEQ. ID. NO. 1 contains an NS2-NS5B region from HCV-1b consensus (con-1) while SEQ. ID. NO. 2 contains a NS3-NS5B region from HCV-1b consensus (con-1). SEQ. ID. NO. 2 also
10   contains useful restriction sites for subcloning NS5B. SEQ. ID. NOs. 1 and 2 both contain a beta-lactamase reporter and a HCV-1a 3' UTR.

      In different embodiments of the present invention, one or more HCV regions from SEQ. ID. NOs. 1 or 2 are replaced with an HCV region from a clinical isolate. Preferably, the region from the clinical isolate is either NS2/3 protease, NS3
15   protease, NS3 helicase, NS5B or a combination thereof.

VIII. Replicon Enhanced Cells

      HCV replicon enhanced cells provide a preferred system for measuring HCV replicon activity. HCV replicon enhanced cells can be isolated based on their
20   ability to support replication of a first replicon and the resulting cell population supports more efficient replication of a second replicon compared to parental cells.

      The replicon enhanced cell supports chronic or persistent replication of the second HCV replicon. Enhanced cells may or may not contain the first HCV replicon used obtain the replicon enhanced cell.

25   The first HCV replicon is defined as the replicon used to select the enhanced cell population and the second replicon is defined as the replicon used to measure HCV replication. Preferably, replicon enhanced cells contain a first HCV replicon having a drug resistance gene and a second HCV replicon having a reporter. The first replicon is present in an amount (copy number) compatible with efficient
30   replication of the second HCV replicon. The combination of the two replicons in a replicon enhanced cell is particularly useful for high throughput screening.

      Different HCV replicons can be constructed for use as the first replicon. A drug resistance gene can be used to isolate cells that support replication of the first replicon. Alternatively, the first replicon can encode a reporter gene that is

compatible with cell sorting which allows isolation of cells that support replication of the first replicon.

The first replicon, if present in a cell containing the second replicon, should be present in an amount compatible with efficient replication of the second

5   HCV replicon. The enhanced phenotype of a replicon enchanced cell can be masked or inhibited if the copy number of the first replicon is too high.

If needed, the copy number of the first replicon can be reduced by treating cells with inhibitors of HCV replication or by using cell culture conditions that are not compatible with replicon replication. The latter includes maintaining the

10   cells at high cell densities for prolonged periods of time. The second replicon can be used to monitor HCV replication in enhanced cells.

Inhibitors of HCV replicon replication include IFN-α and HCV inhibitor compounds targeting a HCV protein. Examples of HCV inhibitory compounds are described in Llinas-Brunet, *et al.*, 2000. *Bioorg Med Chem. Lett.*

15   *10(20)*, 2267-2270.

The first replicon can also be made less active to reduce its copy number. A less active first replicon can be produced in different ways such as by employing regulatory elements or HCV coding sequences that provide for less activity. Regulatory elements that can be altered include ribosome binding sequences,

20   5' UTR, and 3 'UTR sequences. The activity of a replicon can readily be tested by, for example, measuring HCV nucleic acid or protein production.

Different HCV replicons can be constructed for use as the second replicon. The second replicon in addition to containing an HCV sequence preferably contains a reporter sequence. More preferably, the second replicon contains a reporter

25   sequence such as beta-lactamase, beta galactosidase, green fluorescence protein or luciferase.

IX. Detection Methods

Methods for detecting replicon activity include those measuring the

30   production or activity of replicon RNA and encoded protein. Measuring includes qualitative and quantitative analysis. Preferably, replicon activity is measured using a reporter protein. A preferred reporter system is the beta-lactamase reporter system.

Beta-lactamase activity can be measured, for example, by direct visualization of cells using a fluorescence microscope. Quantitation of HCV

35   replication can be accomplished using a CCD camera that acquires digital images and

suitable software that quantitates the number of blue and green cells present in such images. This method quantitates the number of cells in a population that harbors HCV replicons expressing beta-lactamase and this measurement is typically expressed as percentage blue cells (% Blue cells).

5   Another method for measuring beta-lactamase activity is using a fluorescence plate reader that quantitates the amount and green (~530 nm) or blue (~460 nm) fluorescence emitted by cells stimulated with light of ~405 nm. This method can be used for high throughput screening.

Quantitation of beta-lactamase activity can also be accomplished by
10   FACS. This method quantitates the number of blue and green cells in a given cell population as well as the amount of blue and green fluorescence. Instruments capable of cell sorting can be used to isolate cells harboring HCV replicons expressing beta-lactamase.

Techniques suitable for measuring RNA production include those
15   detecting the presence or activity of RNA. The presence of RNA can be detected using, for example, complementary hybridization probes or quantitative PCR. Techniques for measuring hybridization between complementary nucleic acid and quantitative PCR are well known in the art. (See for example, Ausubel, *Current Protocols in Molecular Biology*, John Wiley, 1987-1998, Sambrook, *et al.*, *Molecular*
20   *Cloning, A Laboratory Manual*, 2nd Edition, Cold Spring Harbor Laboratory Press, 1989, and U.S. Patent No. 5,731,148.)

RNA enzymatic activity can be provided to the replicon by using a ribozyme sequence. Ribozyme activity can be measured using techniques detecting the ability of the ribozyme to cleave a target sequence.

25   Techniques for measuring protein production include those detecting the presence or activity of a produced protein. The presence of a particular protein can be determined by, for example, immunological techniques. Protein activity can be measured based on the activity of an HCV protein or a reporter protein sequence.

Techniques for measuring HCV protein activity vary depending upon
30   the protein that is measured. Techniques for measuring the activity of different non-structural proteins such as NS2/3, NS3, and NS5B, are well known in the art. (See, for example, references provided in the Background of the Invention.)

Assays measuring replicon activity also include those detecting virion production from a replicon that produces a virion; and those detecting a cytopathic

effect from a replicon producing proteins exerting such an effect. Cytopathic effects can be detected by assays suitable to measure cell viability.

Assays measuring replicon activity can be used to evaluate the ability of a compound to modulate HCV activities. Such assays can be carried out by

5 providing one or more test compounds to a cell expressing an HCV replicon and measuring the effect of the compound on replicon activity. If a preparation containing more than one compound is used and found to modulate replicon activity, individual compounds or smaller groups of compounds can be tested to identify replicon active compounds.

10 HCV inhibitory compounds can be used to produce replicon enhanced cells and compounds having the appropriate pharmacological properties may be therapeutic compounds. The ability of a compound to serve as a therapeutic compound can be confirmed using animal models such as a chimpanzee to measure efficacy and toxicity.

15

X. Examples

Examples are provided below to further illustrate different features of the present invention. The examples also illustrate useful methodology for practicing the invention. These examples do not limit the claimed invention.

20

Example 1. Production Of Replicon Enhanced Cells

This example illustrates the production of replicon enhanced cells. It is not necessary to cure cells from the first replicon to obtain a cell population that is enhanced for replication of a second replicon. A preferred method to achieve this is

25 to use a replicon (first replicon) with replication properties and replicon copy number that are compatible with enhanced replication of a second replicon.

Replicons used in the Example section have the general gene organization: HCV 5'UTR-drug resistance and/or reporter- EMCV IRES- HCV NS proteins-HCV 3'UTR. The replicon nomenclature used in the examples is as follows:

30 the drug resistance and/or reporter gene under control of the HCV IRES is indicated first, the start of the HCV polyprotein is indicated next and the presence of adaptive mutations is indicated last. For example, a replicon harboring the S2204I adaptive mutation, expressing the neo[r] gene and containing the NS3-NS5B HCV NS region is referred to as neo-NS3/si. Replicons expressing Bla instead of neo[r] and containing

35 the NS2-NS5B HCV NS region are referred to as Bla-NS2/si.

The activity of a beta-lactamase replicon (bla-NS3/si) and a replication deficient replicon (bla-NS3/si/gaa), was compared in parental Huh-7 cells, neo-NS3 cells (Huh-7 cells harboring neo-NS2 replicons), neo-NS2 (Huh-7 enhanced cells harboring neo-NS2 replicons) partially cured neo-NS2 cells harboring a reduced

5   number of neo-NS2 replicons and cured neo-NS2 cells that do not contain replicons. Neo-NS2 cells were partially cured using interferon alpha and are referred to as JGEM cells. Neo-NS2 cells were completely cured using a potent inhibitor of HCV replication and are referred to in the examples below as JG884 cells.

Quantitation of the beta-lactamase reporter was used to measure HCV

10   sub-genomic replication and is expressed as the percentage of beta-lactamase positive cells (% blue cells). The percentage of blue cells (%BC) at 24 hours after transfection is close to 100% in both cell lines indicating similar transfection efficiencies (Table 1). The % BC at days 3 & 6 post transfection is a measure of persistent replication.

The experiment described in Table 1 shows that the bla-NS3/si/gaa

15   replicon did not replicate in any of the cell lines analyzed but replication of the bla-NS3/si replicon was readily detected in all cell lines both at day 3 and day 6. The activity of the bla-NS3/si replicon was significantly lower in Huh-7 and neo-NS3 cells than in the neo-NS2 cell lines.

Importantly, the replication efficiency of the bla-NS3/si replicon was

20   comparable in neo-NS2, JGEM, and JG884 cells demonstrating that cells harboring neo-NS2 replicons do not have to be cured to support enhanced replication of a second replicon. In contrast, the activity of the bla-NS3/si replicon in the neo-NS3 cell line was similar to that observed in Huh-7 cells indicating that neo-NS3 cells were not enhanced (Table 1).

25

Table 1. Cells Harboring Neo-NS2 Replicons Are Enhanced For Replication Of A Replicon Expressing Beta-Lactamase			
	% Blue Cells		
Cell type	Day 1	Day 3	Day 6
Huh7	69	4	3
Neo-NS3/si	76	17	7
Neo-NS2/si	81	18	18
JGEM	81	30	28
JG 884	75	12	24

Quantitation of replicon RNA in the different cell lines indicate that neo-NS3 cells produce significantly more RNA per cell than neo-NS2 cells suggesting that the replicon copy number in neo-NS3 cells might be too high for efficient

5   replication of a second replicon (Figure 4). These observations support the hypothesis that there is a threshold of RNA copy number above which cells are not able to efficiently support replication of a second replicon.

The enhanced phenotype of JGEM and JG884 cells is similar to neo-NS2 cells and is manifested as both increased permissiveness (*i.e.*, a greater

10   percentage of transfected cells support replication) and increased persistence (*i.e.*, replicon maintenance). The enhanced phenotype is not dependent on the sequence of the second replicon. The observation that JGEM cells support enhanced replication of replicons harboring adaptive mutants S232I (SI), A227T (AT) and, R465G (RG) (Figure 5) is in agreement with this notion. Moreover, JGEM (Figure 5) but not Huh-

15   7 cells (not shown) can maintain persistent replication of all three replicons for multiple cell passages without the need of drug selection pressure.

Example 2: Use Of Enhanced Cells To Generate A Cell Line To Screen Inhibitors Of HCV Replication

20   Examples of techniques that can be employed to create a stable cell line harboring a second replicon expressing the beta-lactamase reporter and assaying for activity is provided in this example. Replicon enhanced cells containing a first replicon can be produced as described in Example 1.

Enhanced Huh-7 cells are transfected with HCV replicon RNA

25   encoding beta-lactamase. The resulting cell population is expanded using standard cell culture conditions (DMEM supplemented with 10% FCS, 2 mM L-glutamine, 1x non-essential amino acids, Pen/Strep) until the desired number of replicon harboring cells is obtained.

An alternative approach involves cell sorting. Cell sorting can be

30   performed, for example, by separating cell harboring replicons three to six days after transfection from cells that do not harbor the replicon using flow cytometry assisted cell sorting. The population of cells stably maintaining the replicon expressing beta-lactamase is expanded using standard cell culture techniques until sufficient cells (>2 x 10^9) to carry out the screen is obtained. Replicon harboring cells are then aliquoted,

35   frozen and stored in liquid nitrogen.

Prior to use, frozen cells are thawed fresh in the morning of the assay or the day before and diluted in pre-warmed media to 40,000 cells/ml. Cell suspension (50 μl) is plated into 384-well micro-titer plates. The cells are allowed to recover for at least 6 hours at 37°C in the plates before beginning an assay. 1 μl of 25

5   μM clavulanic acid in PBS and 0.25 μl of 500 μM test compounds in DMSO are added to the cells. The assay cell plates are then incubated for 24 hours at 37°C. To the assay plate, 10 μl of 6x CCF4/AM substrate in loading buffer is added with a Multidrop (Labsystems), and the plate incubated for 90 minutes at ambient temperature. The plate is then read from the bottom on a Teacn Spectrafluor Plus

10   (340nm excitation, 460nm and 530nm emissions).

Example 3: Use Of Clavulanic Acid To Sensitize An HCV Replicon Beta-Lactamase
Assay To Inhibitors Of HCV Replication

In the example described below, clavulanic acid is present throughout
15   the assay at a concentration that slightly reduces beta-lactamase activity instead of using it at high concentration that would complete inhibit beta-lactamase activity. Because clavulanic acid is an irreversible inhibitor, it is a more potent inhibitor of beta-lactamase at low enzyme concentrations than at high enzyme concentrations and therefore its inhibitory activity has a more pronounced effect in the background signal

20   than in the foreground signal which in turn explains the enhancement of the signal-to-background ratio from the beta-lactamase reporter.

Table 2 provides results obtained using different concentrations of
clavulanic acid and an HCV NS5B inhibitor.

Table 2. Improved Potency Of An NS5B Inhibitor In The Presence Of Increasing Concentrations Of Clavulanic Acid			
[CA] μM	S/B	Δ	IC_{50} μM
0.00	3.5	1.23	1.3
0.13	5.7	1.22	0.94
0.25	6.0	1.17	0.84
0.50	6.3	0.97	0.54
1.00	5.4	0.81	0.42

25

The experiment in Figure 6 shows that in the absence of clavulanic acid, the half-life of beta-lactamase activity in the replicon assay is approximately 14.9 hours but in the presence of 0.5 μM of clavulanic acid the half life of beta-lactamase activity is 4.7 hours. The lower half life of beta-lactamase in the presence

5   of clavulanic acid improves the signal to noise ratio of a 24 hour assay.

Example 4. Use Of A Beta-Lactamase Reporter System To Enrich Cell Populations
Harboring HCV Replicons

       JGEM cells were lipotransfected with bla-NS2/si (BK 3'-UTR)

10   replicon RNA using DMRIE-C (transfection reagent, Invitrogen Life Technologies) and expanded under standard growth conditions. Cells were stained with CCF4/AM for 90 minutes, dissociated from the flask with 0.25% trypsin/1 mM EDTA, and then suspended in sort buffer (PBS with 0.1% bovine serum albumin and pen/strep).

       Cells were then sorted using Becton-Dickenson FACS Vantage SE cell

15   sorter equipped with Coherent Innova 70C-4 (488 nm) and Coherent 302C Krypton (407 nm) lasers. Optical filters used on the cell sorter were 530/30 and 450/30 bandpass filters separated by a 490 dichroic mirror. Cells were sorted at a rate of 10,000 cells/s.

       Cells staining positive for beta-lactamase expression were collected in

20   complete medium containing 20% fetal calf serum. Medium was replaced the following day with complete medium containing 10% FCS. Cells were assayed for % blue cells by digital image processing at the indicated intervals. Cells maintained replicon for at least two weeks as indicated by the high percentage of cells that stain positive for the beta-lactamase reporter (Table 3).

25

Table 3. Enrichment Of A Cell Population Harboring An HCV Replicon Expressing Beta-Lactamase	
Day Post Sort	% Blue Cells
Pre-sort	10
Day 1	83
Day 4	89
Day 8	82
Day 14	73
Day 15	75

Example 5. Use Of A Beta-Lactamase Reporter System To Identify Functional HCV Sequences

        HCV BK is a genotype 1b clone that is infectious in chimpanzees. BK

5   replicons with and without the NS5A S2204I adaptive mutation were generated and tested for their ability to replicate using the beta-lactamase reporter. The replicon without the S2204I adaptive mutation failed to replicate in JGEM cells, while the replicon with the mutation replicated with modest efficiency.

        A series of BK and con1 chimeras were generated to identify the

10   region(s) that accounts for the different replicative activities of the two replicons. JGEM cells were lipotransfected with chimeric replicon RNAs and then cultured for 4 days under standard growth conditions. As shown in Table 4, replacement of the BK NS3 sequence with that from the con1 replicon resulted in a dramatic improvement in replication. In other BK/con1 chimeras, most of the differences in replication

15   efficiency tracked with the NS3 sequence used while other parts of the genome had more modest or no effects on the observed differences in replication efficiency.

Table 4. Identification Of Functional HCV Sequence Using Beta-Lactamase Reporter System	
Replicon	% Blue Cells
Bla-BK NS3	0.05
Bla-Bk NS3/SI	2.05
Bla-BK NS3 with con 1 NS3	0.13
Bla-BK NS3/SI with con 1 NS3	49.9
Bla-NS3/SI	44.2
Bla-NS3/SI with BK NS3	0.71

Example 6. Production Of Functional Chimeric Replicons For Resistance

20   Phenotyping

        This example illustrates resistance phenotyping with NS5B. BstZ17 I and Cla I restrictions sites were introduced at the 5'- and 3'- ends of the NS5B coding region, respectively. The nucleotide substitutions made to introduce these restriction sites do not affect amino acid coding. The BstZ17 I and Cla I sites are unique in the

25   resulting construct and facilitate rapid subcloning of NS5B sequences from clinical

isolates for phenotypic analysis. As shown in Table 5, the nucleotide changes required to introduce the restriction sites do not affect replication.

Viral RNA was purified from 140 μl of infected patient serum (10^3-10^6 copies/ml) using the Qiagen viral RNA purification kit according to the

5   manufacturer's directions followed by phenol:chloroform extraction and ethanol precipitation. cDNAs were generated by reverse transcription of 1/20 to 1/5 of the sample using a poly(A) oligonucleotide primer and Superscript II reverse transcriptase (Gibco-BRL) according to the manufacturer's guidelines.

NS5B coding regions were amplified by nested PCR using Expand

10   High Fidelity polymerase (Roche). The initial amplification reaction was carried out using a primer that anneals immediately upstream of the NS5B coding region and the poly(A) primer used for reverse transcription. The second amplification used primers (sequences) that anneal at the 5'- and 3'- ends of the NS5B coding region internal to the primers used in the initial PCR reaction.

15   Amplification products were cloned directly into pGEM T-vector (Promega). The NS5B coding regions were subsequently amplified using a sense primer that included Bcl I restriction site and an antisense primer designed to introduce a Cla I site at the 3'-end. Amplification products were subcloned into the corresponding sites of SEQ. ID. NO. 2 to generate chimeric viruses containing the

20   NS5B sequences derived from the clinical samples.

Replication of the chimeric replicons was characterized by using the beta-lactamase reporter assay as described above. As shown in Table 5, functional replicons with NS5B sequences from another genotype 1b isolate and from a genotype 1a isolate were functional in the context of the resistance phenotyping replicon.

25

Table 5. Functional Chimeric Replicons For Resistance Phenotyping	
Replicon	% Blue Cells
Bla-NS3/si con1 NS5B (Cla I)	34.0
Bla-NS3/si (BstZ17 1) con1 NS5B (Cla I)	33.2
Bla-NS3/si (BstZ17 1) HC(1b) NS5B (Cla I)	30.0
Bla-NS3/si (BstZ17 1) RB(1a) NS5B (Cla I)	6.3
Bla-NS3/si (GAA)	0.3

Example 7: Importance of 3'-UTR

NS2 replicon constructs that expressed a beta-lactamase reporter and that contained either the con1 or HCV 1a 3'-UTR were generated using techniques well known in the art. Replication of the resulting replicons was analyzed by digital image processing or using a fluorescent plate reader. As shown in Table 6, the replicon containing the HCV 1a 3'-UTR replicates more efficiently than the corresponding replicon containing the con1 3'-UTR.

Table 6. Enhancement Of Replication With HCV 1a 3'-UTR		
Replicon	% Blue Cells	Em460/Em530 x100
Bla-NS2/BK NS5B with con1 3'-UTR	11.3	14.0
Bla-NS2/BK NS5B with 1a 3'UTR	32.5	41.2
Bla-NS2(con1)/si with con1 3'UTR	23.9	22.3
Bla-NS2(con1)/si with 1a 3' UTR	42.6	56.3
Bla-NS2/si/GAA	0.2	5.3
Mock	0.0	0.0

Other embodiments are within the following claims. While several embodiments have been shown and described, various modifications may be made without departing from the spirit and scope of the present invention.

WHAT IS CLAIMED IS:

    1.   A method of measuring the ability of a compound to alter HCV activity using a beta-lactamase reporter system comprising the steps of:

5   a) combining together said compound, a screening cell and a beta-lactamase substrate under conditions supporting beta-lactamase activity, wherein said screening cell harbors a first HCV replicon comprising a selection sequence and a second HCV replicon comprising a nucleotide sequence encoding a beta-lactamase; and

10   b) measuring the ability of said compound to alter beta-lactamase production.

    2.   The method of claim 1, wherein said cell is a Huh-7 cell or is derived from a Huh-7 cell.

    3.   The method of claim 2, further comprising the use of clavulanic acid in an amount effective to enhance signal-to-background ratio.

    4.   The method of claim 2, wherein said HCV replicon is a chimeric replicon comprising one or more HCV regions from two or more HCV strains, wherein at least one of the regions is a HCV-1a 3' UTR.

    5.   The method of claim 4, wherein at least one of said regions is a non-structural region from a clinical isolate.

    6.   The method of claim 4, wherein said second HCV replicon consists of either a modified version of SEQ ID NO: 1 or a modified version of SEQ ID NO: 2, wherein said modified version of SEQ ID NO:1 contains SEQ ID NO: 1 modified by replacing the NS5B region with a NS5B region from a clinical isolate and said modified version of SEQ ID NO: 2 contains SEQ ID NO: 2 modified by replacing the NS5B region with a NS5B region from a clinical isolate.

    7.   A HCV replicon enhanced cell comprising a first HCV replicon and a second HCV replicon, wherein said first HCV replicon comprises a selection

sequence, said cell supports chronic or persistent replication of said second HCV replicon and said second HCV replicon is different from said first HCV replicon.

8. The HCV replicon enhanced cell of claim 7, wherein said cell is a Huh-7 cell or is derived from a Huh-7 cell.

9. The HCV replicon enhanced cell of claim 8, wherein said second HCV replicon comprises a beta-lactamase reporter.

10. The HCV replicon enhanced cell of claim 9, wherein said second HCV replicon is a chimeric replicon comprising one or more HCV regions from two or more HCV strains, wherein at least one of the regions is a HCV-1a 3' UTR.

11. A method of producing an HCV replicon enhanced cell comprising a first and a second replicon comprising the steps of:

a) introducing into a cell said first HCV replicon, wherein said first replicon comprises a selection sequence,

b) obtaining a replicon enhanced cell, wherein said replicon enhanced cell supports chronic or persistent replication of said first replicon; and

c) introducing into said replicon enhanced cell said second replicon, wherein said second replicon comprising a reporter,

provided that said first replicon is present in an amount compatible with replication of said second replicon.

12. The method of claim 11, wherein said cell is a Huh-7 cell or is derived from a Huh-7 cell.

13. The method of claim 12, further comprising the step of partially curing said first replicon from said cell.

14. The method of claim 13, wherein said reporter is beta-lactamase.

15.   The method of claim 13, wherein said first HCV replicon is a chimeric replicon comprising one or more HCV regions from two or more HCV strains, wherein at least one of the regions is a HCV-1a 3' UTR.

5   16.   The method of claim 15, wherein at least one of said regions is a non-structural region from a clinical isolate.

17.   The method of claim 15, wherein said second HCV replicon consists of either a modified version of SEQ ID NO: 1 or a modified version of SEQ

10   ID NO: 2, wherein said modified version of SEQ ID NO:1 contains SEQ ID NO: 1 modified by replacing the NS5B region with a NS5B region from a clinical isolate and said modified version of SEQ ID NO: 2 contains SEQ ID NO: 2 modified by replacing the NS5B region with a NS5B region from a clinical isolate.

15   18.   A HCV replicon comprising a beta-lactamase reporter, wherein said replicon does not contain a sequence coding for resistance to an agent that inhibits cell growth.

19.   A chimeric HCV replicon comprising one or more HCV

20   regions from two or more HCV strains, wherein at least one of the regions is a HCV-1a 3' UTR.

20.   The chimeric HCV replicon of claim 19, wherein at least one of said regions is a non-structural region from a clinical isolate.

25

21.   The chimeric HCV replicon of claim 19, wherein said HCV replicon consists of either a modified version of SEQ ID NO: 1 or a modified version of SEQ ID NO: 2, wherein said modified version of SEQ ID NO:1 contains SEQ ID NO: 1 modified by replacing the NS5B region with a NS5B region from a clinical

30   isolate and said modified version of SEQ ID NO: 2 contains SEQ ID NO: 2 modified by replacing the NS5B region with a NS5B region from a clinical isolate.

22.   The chimeric HCV replicon of claim 21, wherein said replicon consists of either SEQ ID NO: 1 or SEQ ID NO 2.

35

27

23.   The chimeric HCV replicon of claim 20, wherein said replicon comprises restriction sites not present in naturally occurring HCV that are located about 3' and about 5' from an HCV target region, wherein said restriction sites do not affect replicon activity.

5

24.   The chimeric HCV replicon of claim 23, wherein said restriction sites are silent with respect to amino acid coding.

25.   The chimeric HCV replicon of any one of claims 19, 20, 23, or

10   24, wherein said chimeric replicon comprises a beta-lactamase reporter.

26.   The chimeric HCV replicon of claim 25, wherein said replicon does not contain a sequence coding for resistance to an agent that inhibits cell growth.

1/12

```
   1 gccagccccc gauugggggc gacacuccac cauagaucac uccccuguga ggaacuacug
  61 ucuucacgca gaaagcgucu agccauggcg uuaguaugag ugucgugcag ccuccaggac
 121 ccccccuccc gggagagcca uaguggucug cggaaccggu gaguacaccg gaauugccag
 181 gacgaccggg uccuuucuug gaucaacccg cucaaugccu ggagauuugg gcgugccccc
 241 gcgagacugc uagccaguga uguuggguc gcgaaaggcc uugugguacu gccugauagg
 301 gugcuugcga gugcccggg aggucucgua gaccgugcac caugagcacg aauccuaaac
 361 cucaaagaaa aaccaaaggg cgcgccaugc acccagaaac gcuggugaaa guaaaagaug
 421 cugaagauca guugggugca cgaguggguu acaucgaacu ggaucucaac agcgguaaga
 481 uccuugagag uuuucgcccc gaagaacguu uuccaaugau gagcacuuuu aaaguucugc
 541 uauguggcgc gguauuaucc cguauugacg ccgggcaaga gcaacucggu cgccgcauac
 601 acuauucuca gaaugacuug guugaguacu caccagucac agaaaagcau cuuacggaug
 661 gcaugacagu aagagaauua ugcagugcug ccauaaccau gagugauaac acugcggcca
 721 acuuacuucu gacaacgauc ggaggaccga aggagcuaac cgcuuuuuug cacaacaugg
 781 gggaucaugu aacucgccuu gaucguuggg aaccggagcu gaaugaagcc auaccaaacg
 841 acgagcguga caccacgaug ccuguagcaa uggcaacaac guugcgcaaa cuauuaacug
 901 gcgaacuacu uacucuagcu ucccggcaac aauuaauaga cuggauggag gcggauaaag
 961 uugcaggacc acuucugcgc ucggcccuuc cggcuggcug guuuauugcu gauaaaucug
1021 gagccgguga gcgugggucu cgcgguauca uugcagcacu ggggccagau gguaagcccu
1081 cccguaucgu aguuaucuac acgacgggga gucaggcaac uauggaugaa cgaaauagac
1141 agaucgcuga gauaggugcc ucacugauua agcauuggua aguuuaaaca gaccacaacg
1201 guuucccucu agcgggauca auuccgcccc ucccuccc ccccccuaa cguuacuggc
1261 cgaagccgcu uggaauaagg ccggugugcg uuugucuaua uguuauuuuc caccauauug
1321 ccgucuuuug gcaaugugag ggcccggaaa ccuggccug ucuucuugac gagcauuccu
1381 aggggucuuu ccccucucgc caaaggaaug caaggucugu ugaaugucgu gaaggaagca
1441 guuccucugg aagcuucuug aagacaaaca acgucuguag cgacccuuug caggcagcgg
1501 aacccccac cuggcgacag gugccucugc ggccaaaagc cacguguaua agauacaccu
1561 gcaaaggcgg cacaaccccca gugccacguu gugaguugga uaguuguga aagagucaaa
1621 uggcucuccu caagcguauu caacaagggg cugaaggaug cccagaaggu accccauugu
1681 augggaucug aucuggggcc ucggugcaca ugcuuuacau guguuuaguc gagguuaaaa
1741 aacgucuagg cccccgaac cacggggacg ugguuuuccu uugaaaaaca cgauaauacc
1801 auggaccggg agauggcagc aucgugcgga ggcgcgguuu ucguaggucu gauacucuug
1861 accugcac cgcacuauaa gcuguuccuc gcuaggcuca uauggugguu acaauauuuu
1921 aucaccaggg ccgaggcaca cuugcaagug uggaucccccc cccucaacgu ucgggggggc
1981 cgcgaugccg ucauccuccu cacgugcgcg auccacccag agcuaaucuu uaccaucacc
2041 aaaaucuugc ucgccauacu cgguccacuc auggugcucc aggcgguau aaccaaagug
2101 ccguacuucg ugcgcgcaca cgggcucauu cgugcaugca ugcuggugcg gaagguugcu
2161 gggggucauu auguccaaau ggcucucaug aaguuggccg cacugacagg uacguacguu
2221 uaugaccauc ucaccccacu gcgggacugg gcccacgcgg ccuacgaga ccuugcggug
2281 gcaguugagc ccgucgucuu cucugauaug gagaccaagg uuaucaccug gggggcagac
2341 accgcggcgu gugggacau caucuugggc cugcccgucu ccgcccgcag ggggagggag
2401 auacaucugg gaccggcaga cagccuugaa gggcaggggu ggcgacuccu cgcgccuauu
2461 acggccuacu cccaacagac gcgaggccua cuuggcugca ucaucacuag ccucacaggc
```

FIG. 1A

```
2521 cgggacagga accaggucga gggggagguc caaguggucu ccaccgcaac acaaucuuuc
2581 cuggcgaccu gcgucaaugg cgugucguugg acugucuauc augguggccgg cucaaagacc
2641 cuugccggcc caaagggccc aaucacccaa auguacacca auguggacca ggaccucguc
2701 ggcuggcaag cgccccccgg ggcgcguucc uugacaccau gcaccugcgg cagcucggac
2761 cuuuacuugg ucacgaggca ugccgauguc auuccggugc gccggcgggg cgacagcagg
2821 gggagccuac ucucccccag gcccgucucc uacuugaagg gcucuucggg cgguccacug
2881 cucugccccu cggggcacgc uguggggcauc uuucgggcug ccgugugcac ccgaggggguu
2941 gcgaaggcgg uggacuuugu acccgucgag ucuauggaaa ccacuaugcg gucccccgguc
3001 uucacggaca acucgucccc uccggccgua ccgcagacau uccagguggc ccaucuacac
3061 gccccuacug guagcggcaa gagcacuaag gugccggcug cguaugcagc ccaaggguau
3121 aaggugcuug uccugaaccc guccgucgcc gccacccuag guuucggggc guauaugucu
3181 aaggcacaug guaucgaccc uaacaucaga accgggguaa ggaccaucac cacggugcc
3241 cccaucacgu acuccaccua uggcaaguuu cuugccgacg guguugcuc uggggggcgcc
3301 uaugacauca uaauauguga ugagugccac ucaacugacu cgaccacuau ccugggcauc
3361 ggcacagucc uggaccaagc ggagacggcu ggagcgcgac ucgucgugcu cgccaccgcu
3421 acgccuccgg gaucggucac cgugccacau ccaaacaucg aggaggguggc ucuguccagc
3481 acuggagaaa uccccuuuua uggcaaagcc auccccaucg agaccaucaa ggggggggagg
3541 caccucauuu ucugccauuc caagaagaaa ugugaugagc ucgccgcgaa gcuguccggc
3601 cucggacuca augcuguagc auauuaccgg ggccuugaug uauccgucau accaacuagc
3661 ggagacguca uugucguagc aacggacgcu cuaaugacgg gcuuuaccgg cgauuucgac
3721 ucagugaucg acugcaauac augugucacc cagacagucg acuucagccu ggacccgacc
3781 uucaccauug agacgacgac cgugccacaa gacgcggugu cacgcucgca gcggcgaggc
3841 aggacuggua ggggcaggau gggcauuuac agguuuguga .cuccaggaga acggcccucg
3901 ggcauguucg auuccucggu ucugugcgag ugcuaugacg cgggcugugc uugguacgag
3961 cucacgcccg ccgagaccuc aguuagguug cgggcuuacc uaaacacacc aggguugccc
4021 gucugccagg accaucugga guucugggag agcgucuuua caggccucac ccacauagac
4081 gcccauuucu uguccccagac uaagcaggca ggagacaacu uccccuaccu gguagcauac
4141 caggcuacgg ugugcgccag ggcucaggcu ccaccuccau cguggggacca aauguggaag
4201 ugucucauac ggcuaaagcc uacgcugcac gggccaacgc cccugcugua uaggcuggga
4261 gccguucaaa acgagguuac uaccacacac cccauaacca aauacaucau ggcaugcaug
4321 ucggcugacc uggaggucgu cacgagcacc ugggugcugg uaggcggagu ccuagcagcu
4381 cuggccgcgu auugccugac aacaggcagc guggucauug ugggcaggau caucuugucc
4441 ggaaagccgg ccaucauucc cgacagggaa guccuuuacc gggaguucga ugagauggaa
4501 gagugcgccu cacaccuccc uuacaucgaa cagggaaugc agcucgccga acaauucaaa
4561 cagaaggcaa ucggguugcu gcaaacagcc accaagcaag cggaggcugc ugcucccgug
4621 guggaaucca aguggcggac ccucgaagcc uucugggcga agcauaugug gaauuucauc
4681 agcgggauac aauauuuagc aggcuugucc acucugccug gcaaccccgc gauagcauca
4741 cugauggcau ucacagccuc uaucaccagc ccgcucacca cccaacauac ccuccuguuu
4801 aacauccugg ggggauggguu ggccgcccaa cuugcuccuc ccagcgcugc uucugcuuuc
4861 guaggcgccg gcaucgcugg agcggcuguu ggcagcauag gccuuggggaa ggugcuugug
4921 gauauuuugg cagguuuaugg agcaggggug gcaggcgcgc ucguggccuu uaaggucaug
4981 agcggcgaga ugcccuccac cgaggaccug guuaaccuac ucccugcuau ccucucccu
```

FIG. 1B

```
5041 ggcgcccuag ucgucggggu cgugugcgca gcgauacugc gucggcacgu gggcccaggg
5101 gaggggggcug ugcaguggau gaaccggcug auagcguucg cuucgcgggg uaaccacguc
5161 uccccacgc acuaugugcc ugagagcgac gcugcagcac gugucacuca gauccucucu
5221 agucuuacca ucacucagcu gcugaagagg cuucaccagu ggaucaacga ggacugcucc
5281 acgccaugcu ccggcucgug gcuaagagau guuugggauu ggauaugcac gguguugacu
5341 gauuucaaga ccuggcucca guccaagcuc cugccgcgau ugccgggagu ccccuucuuc
5401 ucaugucaac gugggguacaa gggagucugg cggggcgacg gcaucaugca aaccaccugc
5461 ccauguggag cacagaucac cggacaugug aaaaacgguu ccaugaggau cgugggggccu
5521 aggaccugua guaacacgug gcauggaaca uuccccauua acgcguacac cacgggcccc
5581 ugcacgcccu ccccggcgcc aaauuauucu agggcgcugu ggcggguggc ugcugaggag
5641 uacguggagg uuacgcgggu gggggauuuc cacuacguga cgggcaugac cacugacaac
5701 guaaagugcc cgugucaggu uccggccccc gaauucuuca cagaagugga ugggggugcgg
5761 uugcacaggu acgcuccagc gugcaaaccc cuccuacggg aggaggucac auuccugguc
5821 gggcucaauc aauaccuggu ugggucacag cucccaugcg agcccgaacc ggacguagca
5881 gugcucacuu ccaugcucac cgaccccucc cacauuacgg cggagacggc uaagcguagg
5941 cuggccaggg gaucucccccc cuccuuggcc agcucaucag cuauccagcu gucugcgccu
6001 uccuugaagg caacaugcac uacccgucau gacuccccgg acgcugaccu caucgaggcc
6061 aaccuccugu ggcggcagga gaugggcggg aacaucaccc gcguggaguc agaaaauaag
6121 guaguaauuu uggacucuuu cgagccgcuc caagcggagg aggaugagag ggaaguaucc
6181 guuccggcgg agauccugcg gagguccagg aaauucccuc gagcgaugcc cauaugggca
6241 cgcccggauu acaacccucc acuguuagag uccuggaagg acccggacua cgucccucca
6301 gugguacacg ggguguccauu gccgccugcc aaggccccuc cgauaccacc uccacggagg
6361 aagaggacgg uuguccuguc agaaucuacc gugucuucug ccuuggcgga gcucgccaca
6421 aagaccuucg gcagcuccga aucgucggcc gucgacagcg gcacggcaac ggccucuccu
6481 gaccagcccu ccgacgacgg cgacgcggga uccgacguug agucguacuc cuccaugccc
6541 ccccuugagg gggagccggg ggaucccgau cucagcgacg ggucuugguc uaccguaagc
6601 gaggaggcua gugaggacgu cgucugcugc ucgauguccu acacauggac aggcgcccug
6661 aucacgccau gcgcugcgga ggaaaccaag cugcccauca augcacugag caacucuuug
6721 cuccgucacc acaacuuggu cuaugcuaca acaucucgca gcgcaagccu gcggcagaag
6781 aaggucaccu uugacagacu gcagguccug gacgaccacu accgggacgu gcucaaggag
6841 augaaggcga aggcguccac aguuaaggcu aaacuucuau ccguggagga agccuguaag
6901 cugacgcccc cacauucggc cagaucuaaa uuuggcuaug gggcaaagga cgucccggaac
6961 cuauccagca aggccguuaa ccacauccgc uccgugugga aggacuugcu ggaagacacu
7021 gagacaccaa uugacaccac caucauggca aaaaaugagg uuuucugcgu ccaaccagag
7081 aaggggggcc gcaagccagc ucgccuuauc guauucccag auuugggggu ucgugugugc
7141 gagaaaaugg cccuuuacga ugugguccucc accucccucc aggccgugau gggcucuuca
7201 uacggauucc aauacucucc uggacagcgg gucgaguucc uggugaaugc cuggaaagcg
7261 aagaaaugcc cuaugggcuu cgcauaugac acccgcuguu uugacucaac ggucacgag
7321 aaugacaucc guguugagga gucaaucuac caauguugug acuuggcccc cgaagccaga
7381 caggccauaa ggucgcucac agagcggcuu uacaucgggg gcccccugac uaauucuaaa
7441 gggcagaacu gcgggcuaucg ccgggugccgc gcgagcggug uacugacgac cagcugcggu
7501 aauacccuca cauguuacuu gaaggccgcu gcggccuguc gagcugcgaa gcuccaggac
```

FIG. 1C

4/12

```
7561 ugcacgaugc ucguaugcgg agacgaccuu gucguuaucu gugaaagcgc ggggacccaa
7621 gaggacgagg cgagccuacg ggccuucacg gaggcuauga cuagauacuc ugcccccccu
7681 ggggacccgc ccaaaccaga auacgacuug gaguugauaa caucaugcuc cuccaaugug
7741 ucagucgcgc acgaugcauc uggcaaaagg guguacuauc ucacccguga ccccaccacc
7801 ccccuugcgc gggcugcgug ggagacagcu agacacacuc cagucaauuc cuggcuaggc
7861 aacaucauca uguaugcgcc caccuugugg gcaaggauga uccugaugac ucauuucuuc
7921 uccauccuuc uagcucagga acaacuugaa aaagcccuag auugucagau cuacggggcc
7981 uguuacucca uugagccacu ugaccuaccu cagaucauuc aacgacucca uggccuuagc
8041 gcauuuucac uccauaguua cucuccaggu gagaucaaua ggguggcuuc augccucagg
8101 aaacuugggg uaccgcccuu gcgagucugg agacaucggg ccagaagugu ccgcgcuagg
8161 cuacuguccc aggggggggag ggcugccacu uguggcaagu accucuucaa cugggcagua
8221 aggaccaagc ucaaacucac uccaaucccg gcugcguccc aguuggauuu auccagcugg
8281 uucguugcug guuacagcgg gggagacaua uaucacagcc ugucucgugc ccgaccccgc
8341 ugguucaugu ggugccuacu ccuacuuucu guaggggguag gcaucuaucu acuccccaau
8401 cgaugaaggu uggggguaaac acuccggccu cuuaggccau uuccucucuu uuuuuuguuu
8461 uuuuggguuu uuuuguuuuu uuucuuuuuu uuuuuuuuuu uuucuuuuuu ccuucuuccu
8521 uuucucuuuu uuucuucuuu aaugguggcu ccaucuuagc ccuagucacg gcuagcugug
8581 aaagguccgu gagccgcaug acugcagaga gugcugauac uggccucucu gcagaucaug
8641 ugggucggca uggcaucucc accuccucgc gguccgaccu gggcauccga aggaggacgu
8701 cguccacucg gauggcuaag ggagagcucu ag
```

FIG. 1D

```
   1 gccagccccc gattgggggc gacactccac catagatcac tcccctgtga ggaactactg
  61 tcttcacgca gaaagcgtct agccatggcg ttagtatgag tgtcgtgcag cctccaggac
 121 cccccctccc gggagagcca tagtggtctg cggaaccggt gagtacaccg gaattgccag
 181 gacgaccggg tcctttcttg gatcaacccg ctcaatgcct ggagatttgg gcgtgccccc
 241 gcgagactgc tagccgagta gtgttgggtc gcgaaaggcc ttgtggtact gcctgatagg
 301 gtgcttgcga gtgccccggg aggtctcgta gaccgtgcac catgagcacg aatcctaaac
 361 ctcaaagaaa aaccaaaggg cgcgccatgc acccagaaac gctggtgaaa gtaaaagatg
 421 ctgaagatca gttgggtgca cgagtgggtt acatcgaact ggatctcaac agcggtaaga
 481 tccttgagag ttttcgcccc gaagaacgtt ttccaatgat gagcactttt aaagttctgc
 541 tatgtggcgc ggtattatcc cgtattgacg ccgggcaaga gcaactcggt cgccgcatac
 601 actattctca gaatgacttg gttgagtact caccagtcac agaaaagcat cttacggatg
 661 gcatgacagt aagagaatta tgcagtgctg ccataaccat gagtgataac actgcggcca
 721 acttacttct gacaacgatc ggaggaccga aggagctaac cgcttttttg cacaacatgg
 781 gggatcatgt aactcgcctt gatcgttggg aaccggagct gaatgaagcc ataccaaacg
 841 acgagcgtga ccaccgatgg cctgtagcaa tggcaacaac gttgcgcaaa ctattaactg
 901 gcgaactact tactctagct tcccggcaac aattaataga ctggatggag gcggataaag
 961 ttgcaggacc acttctgcgc tcggcccttc cggctggctg gtttattgct gataaatctg
1021 gagccggtga gcgtgggtct cgcggtatca ttgcagcact ggggccagat ggtaagccct
1081 cccgtatcgt agttatctac acgacgggga gtcaggcaac tatggatgaa cgaaatagac
1141 agatcgctga gataggtgcc tcactgatta agcattggta agtttaaaca gaccacaacg
1201 gtttccctct agcgggatca attccgcccc tctccctccc ccccccctaa cgttactggc
1261 cgaagccgct tggaataagg ccggtgtgcg tttgtctata tgttattttc caccatattg
1321 ccgtcttttg gcaatgtgag ggcccggaaa cctggccctg tcttcttgac gagcattcct
1381 aggggtcttt cccctctcgc caaaggaatg caaggtctgt tgaatgtcgt gaaggaagca
1441 gttcctctgg aagcttcttg aagacaaaca acgtctgtag cgaccctttg caggcagcgg
1501 aaccccccac ctggcgacag gtgcctctgc ggccaaaagc cacgtgtata agatacacct
1561 gcaaaggcgg cacaacccca gtgccacgtt gtgagttgga tagttgtgga aagagtcaaa
1621 tggctctcct caagcgtatt caacaagggg ctgaaggatg cccagaaggt accccattgt
1681 atgggatctg atctggggcc tcggtgcaca tgctttacat gtgtttagtc gaggttaaaa
1741 aacgtctagg cccccccgaac cacggggacg tggttttcct ttgaaaaaca cgataatacc
1801 atggcgccta ttacggccta ctcccaacag acgcgaggcc tacttggctg catcatcact
1861 agcctcacag gccgggacag gaaccaggtc gagggggagg tccaagtggt ctccaccgca
1921 acacaatctt tcctggcgac ctgcgtcaat ggcgtgtgtt ggactgtcta tcatggtgcc
1981 ggctcaaaga cccttgccgg cccaaagggc ccaatcaccc aaatgtacac caatgtggac
2041 caggacctcg tcggctggca agcgcccccc ggggcgcgtt ccttgacacc atgcacctgc
2101 ggcagctcgg acctttactt ggtcacgagg catgccgatg tcattccggt gcgccggcgg
2161 ggcgacagca gggggagcct actctccccc aggcccgtct cctacttgaa gggctcttcg
2221 ggcggtccac tgctctgccc ctcggggcac gctgtgggca tctttcgggc tgccgtgtgc
2281 acccgagggg ttgcgaaggc ggtggacttt gtaccgtcg agtctatgga aaccactatg
2341 cggtccccgg tcttcacgga caactcgtcc cctccggccg taccgcagac attccaggtg
2401 gcccatctac acgcccctac tggtagcggc aagagcacta aggtgccggc tgcgtatgca
2461 gcccaagggt ataaggtgct tgtcctgaac ccgtccgtcg ccgccaccct aggtttcggg
```

FIG. 2A

```
2521 gcgtatatgt ctaaggcaca tggtatcgac cctaacatca gaaccggggt aaggaccatc
2581 accacgggtg cccccatcac gtactccacc tatggcaagt ttcttgccga cggtggttgc
2641 tctgggggcg cctatgacat cataatatgt gatgagtgcc actcaactga ctcgaccact
2701 atcctgggca tcggcacagt cctggaccaa gcggagacgg ctggagcgcg actcgtcgtg
2761 ctcgccaccg ctacgcctcc gggatcggtc accgtgccac atccaaacat cgaggaggtg
2821 gctctgtcca gcactggaga aatccccttt tatggcaaag ccatccccat cgagaccatc
2881 aagggggga ggcacctcat tttctgccat tccaagaaga aatgtgatga gctcgccgcg
2941 aagctgtccg gcctcggact caatgctgta gcatattacc ggggccttga tgtatccgtc
3001 ataccaacta gcggagacgt cattgtcgta gcaacggacg ctctaatgac gggctttacc
3061 ggcgatttcg actcagtgat cgactgcaat acatgtgtca cccagacagt cgacttcagc
3121 ctggacccga ccttcaccat tgagacgacg accgtgccac aagacgcggt gtcacgctcg
3181 cagcggcgag caggactgg tagggggcagg atgggcattt acaggtttgt gactccagga
3241 gaacggccct cgggcatgtt cgattcctcg gttctgtgcg agtgctatga cgcgggctgt
3301 gcttggtacg agctcacgcc cgccgagacc tcagttaggt tgcgggctta cctaaacaca
3361 ccagggttgc ccgtctgcca ggaccatctg gagttctggg agagcgtctt tacaggcctc
3421 acccacatag acgcccattt cttgtcccag actaagcagg caggagacaa cttcccctac
3481 ctggtagcat accaggctac ggtgtgcgcc agggctcagg ctccacctcc atcgtgggac
3541 caaatgtgga agtgtctcat acggctaaag cctacgctgc acgggccaac gccctgctg
3601 tataggctgg gagccgttca aaacgaggtt actaccacac accccataac caaatacatc
3661 atggcatgca tgtcggctga cctggaggtc gtcacgagca cctgggtgct ggtaggcgga
3721 gtcctagcag ctctggccgc gtattgcctg acaacaggca gcgtggtcat tgtgggcagg
3781 atcatcttgt ccggaaagcc ggccatcatt cccgacaggg aagtcctta ccgggagttc
3841 gatgagatgg aagagtgcgc ctcacacctc ccttacatcg aacagggaat gcagctcgcc
3901 gaacaattca aacagaaggc aatcggggttg ctgcaaacag ccaccaagca agcggaggct
3961 gctgctcccg tggtggaatc caagtggcgg accctcgaag ccttctgggc gaagcatatg
4021 tggaatttca tcagcgggat acaatattta gcaggcttgt ccactctgcc tggcaacccc
4081 gcgatagcat cactgatggc attcacagcc tctatcacca gcccgctcac cacccaacat
4141 accctcctgt ttaacatcct gggggggatgg gtggccgccc aacttgctcc tcccagcgct
4201 gcttctgctt tcgtaggcgc cggcatcgct ggagcggctg ttggcagcat aggccttggg
4261 aaggtgcttg tggatatttt ggcaggttat ggagcagggg tggcaggcgc gctcgtggcc
4321 tttaaggtca tgagcggcga gatgccctcc accgaggacc tggttaacct actccctgct
4381 atcctctccc ctggcgccct agtcgtcggg gtcgtgtgcg cagcgatact gcgtcggcac
4441 gtgggcccag gggaggggc tgtgcagtgg atgaaccggc tgatagcgtt cgcttcgcgg
4501 ggtaaccacg tctcccccac gcactatgtg cctgagagcg acgctgcagc acgtgtcact
4561 cagatcctct ctagtcttac catcactcag ctgctgaaga ggcttcacca gtggatcaac
4621 gaggactgct ccacgccatg ctccggctcg tggctaagag atgtttggga ttggatatgc
4681 acggtgttga ctgatttcaa gacctggctc cagtccaagc tcctgccgcg attgccggga
4741 gtcccccttct tctcatgtca acgtgggtac aagggagtct ggcggggcga cggcatcatg
4801 caaaccacct gcccatgtgg agcacagatc accggacatg tgaaaaacgg ttccatgagg
4861 atcgtggggc ctaggacctg tagtaacacg tggcatggaa cattccccat taacgcgtac
4921 accacgggcc cctgcacgcc ctccccggcg ccaaattatt ctagggcgct gtggcgggtg
4981 gctgctgagg agtacgtgga ggttacgcgg gtgggggatt ccactacgt gacgggcatg
```

FIG. 2B

```
5041 accactgaca acgtaaagtg cccgtgtcag gttccggccc ccgaattctt cacagaagtg
5101 gatggggtgc ggttgcacag gtacgctcca gcgtgcaaac ccctcctacg ggaggaggtc
5161 acattcctgg tcgggctcaa tcaatacctg gttgggtcac agctcccatg cgagcccgaa
5221 ccggacgtag cagtgctcac ttccatgctc accgacccct cccacattac ggcggagacg
5281 gctaagcgta ggctggccag gggatctccc ccctccttgg ccagctcatc agctgcccag
5341 ctgtctgcgc cttccttgaa ggcaacatgc actacccgtc atgactcccc ggacgctgac
5401 ctcatcgagg ccaacctcct gtggcggcag gagatgggcg ggaacatcac ccgcgtggag
5461 tcagaaaata aggtagtaat tttggactct ttcgagccgc tccaagcgga ggaggatgag
5521 agggaagtat ccgttccggc ggagatcctg cggaggtcca ggaaattccc tcgagcgatg
5581 cccatatggg cacgcccgga ttacaaccct ccactgttag agtcctggaa ggacccggac
5641 tacgtccctc cagtggtaca cgggtgtcca ttgccgcctg ccaaggcccc tccgatacca
5701 cctccacgga ggaagaggac ggttgtcctg tcagaatcta ccgtgtcttc tgccttggcg
5761 gagctcgcca caaagacctt cggcagctcc gaatcgtcgg ccgtcgacag cggcacggca
5821 acggcctctc ctgaccagcc ctccgacgac ggcgacgcgg gatccgacgt tgagtcgtac
5881 tcctccatgc ccccccttga ggggggaaccg ggggacccccg atctcagtga cgggtcttgg
5941 tctaccgtga gcgaggaagc tagtgaggat gtcgtctgct gctcaatgtc gtatacatgg
6001 acaggcgcct tgatcacgcc atgcgctgcg gaggaaagca agctgcccat caacgcgttg
6061 agcaactctt tgctgcgcca ccataacatg gtttatgcca caacatctcg cagcgcaggc
6121 ctgcggcaga agaaggtcac ctttgacaga ctgcaagtcc tggacgacca ctaccgggac
6181 gtgctcaagg agatgaaggc gaaggcgtcc acagttaagg ctaaactcct atccgtagag
6241 gaagcctgca agctgacgcc cccacattcg gccaaatcca agtttggcta tggggcaaag
6301 gacgtccgga acctatccag caaggccgtt aaccacatcc actccgtgtg gaaggacttg
6361 ctggaagaca ctgtgacacc aattgacacc accatcatgg caaaaaatga ggttttctgt
6421 gtccaaccag agaaaggagg ccgtaagcca gcccgcctta tcgtattccc agatctggga
6481 gtccgtgtat gcgagaagat ggccctctat gatgtggtct ccaccttcc tcaggtcgtg
6541 atgggctcct catacggatt ccagtactct cctgggcagc gagtcgagtt cctggtgaat
6601 acctggaaat caaagaaaaa ccccatgggc ttttcatatg acactcgctg tttcgactca
6661 acggtcaccg agaacgacat ccgtgttgag gagtcaattt accaatgttg tgacttggcc
6721 cccgaagcca gacaggccat aaaatcgctc acagagcggc tttatatcgg gggtcctctg
6781 actaattcaa aagggcagaa ctgcggttat cgccggtgcc gcgcgagcgg cgtgctgacg
6841 actagctgcg gtaacaccct cacatgttac ttgaaggcct ctgcagcctg tcgagctgcg
6901 aagctccagg actgcacgat gctcgtgaac ggagacgacc ttgtcgttat ctgtgaaagc
6961 gcgggaaccc aagaggacgc ggcgagccta cgagtcttca cggaggctat gactaggtac
7021 tctgcccccc ccgggggaccc gccccaacca gaatacgact tggagctgat aacatcatgt
7081 tcctccaatg tgtcggtcgc ccacgatgca tcaggcaaaa gggtgtacta cctcacccgt
7141 gatcccacca cccccctcgc acgggctgcg tgggaaacag ctagacacac tccagttaac
7201 tcctggctag gcaacattat catgtatgcg cccactttgt gggcaaggat gattctgatg
7261 actcacttct tctccatcct tctagcacag gagcaacttg aaaaagccct ggactgccag
7321 atctacgggg cctgttactc cattgagcca cttgacctac ctcagatcat tgaacgactc
7381 catggcctta gcgcatttt actccatagt tactctccag gtgagatcaa tagggtggct
7441 tcatgcctca ggaaacttgg ggtaccgccc ttgcgagctt ggagacaccg ggcccggaat
7501 gtccgcgcta ggcttctgtc cagaggaggc agggctgcca tatgtggcaa gtacctcttc
```

FIG. 2C

```
7561  aactgggcag  taaggacaaa  gcttaaactc  actccaatag  cggccgctgg  ccggctggac
7621  ttgtccagct  ggttcacggc  tggctacagc  gggggagaca  tttatcacgg  cgtgtctcat
7681  gcccggcccc  gctggttctg  gttttgccta  ctcctgctcg  ctgcaggaat  aggcatctac
7741  ctcctcccca  atcgatgaag  gttggggtaa  acactccggc  ctcttaggcc  atttcctctc
7801  ttttttttgt  ttttttgggt  ttttttgttt  tttttctttt  tttttttttt  tttttctttt
7861  ttccttcttc  cttttctctt  tttttcttct  ttaatggtgg  ctccatctta  gccctagtca
7921  cggctagctg  tgaaaggtcc  gtgagccgca  tgactgcaga  gagtgctgat  actggcctct
7981  ctgcagatca  tgtgggtcgg  catggcatct  ccacctcctc  gcggtccgac  ctgggcatcc
8041  gaaggaggac  gtcgtccact  cggatggcta  agggagagct  ctaga
```

FIG. 2D

A.

B.

FIG. 3

FIG. 4

FIG. 5

FIG. 6

SEQUENCE LISTING

<110> Merck & Co., Inc.

<120> HEPATITIS C VIRUS ASSAY SYSTEMS

<130> PCT 21080

<150> 60/372,847
<151> 2002-04-16

<160> 2

<170> FastSEQ for Windows Version 4.0

<210> 1
<211> 8732
<212> RNA
<213> Artificial Sequence

<220>
<223> HCV replicon

<400> 1
gccagccccc gauuggggggc gacacuccac cauagaucac uccccuguga ggaacuacug 60
ucuucacgca gaaagcgucu agccauggcg uuaguaugag ugucgugcag ccuccaggac 120
cccccuccc gggagagcca uaguggucug cggaaccggu gaguacaccg gaauugccag 180
gacgaccggg uccuuucuug gaucaacccg cucaaugccu ggagauuugg gcgugccccc 240
gcgagacugc uagccgagua guguugggguc gcgaaaggcc uugugguacu gccugauagg 300
gugcuugcga gugccccggg aggucucgua gaccgugcac caugagcacg aauccuaaac 360
cucaaagaaa aaccaaaggg cgcgccaugc acccagaaac gcuggugaaa guaaaagaug 420
cugaagauca guuggggugca cgaguggguu acaucgaacu ggaucucaac agcgguaaga 480
uccuugagag uuuucgcccc gaagaacguu uuccaaugau gagcacuuuu aaaguucugc 540
uauguggcgc gguauuaucc cguauugacg ccgggcaaga gcaacucggu cgccgcauac 600
acuauucuca gaaugacuug guugaguacu caccagucac agaaaagcau cuuacggaug 660
gcaugacagu aagagaauua ugcagugcug ccauaaccau gaguugauaac acugcggcca 720
acuuacuucu gacaacgauc ggaggaccga aggagcuaac cgcuuuuuug cacaacaugg 780
gggaucaugu aacucgccuu gaucguuggg aaccggagcu gaaugaagcc auaccaaacg 840
acgagcguga caccacgaug ccuguagcaa uggcaacaac guugcgcaaa cuauuaacug 900
gcgaacuacu uacucuagcu ucccggcaac aauuaauaga cuggauggag gcggauaaag 960
uugcaggacc acuucugcgc ucggcccuuc cggcuggcug guuuauugcu gauaaaucug 1020
gagccgguga gcgugggucu cgcgguauca uugcagcacu ggggccagau gguaagcccu 1080
cccguaucgu aguuaucuac acgacgggga gucaggcaac uauggaugaa cgaaauagac 1140
agaucgcuga gauaggugcc ucacugauua agcauuggua aguuuaaaca gaccacaacg 1200
guuucccucu agcgggauca auuccgcccc ucuccccucc cccccccuaa cguuacuggc 1260
cgaagccgcu uggaauaagg ccgguguguucg uuugucuaua uguuauuuuc caccauauug 1320
ccgucuuuug gcaaugugag ggcccggaaa ccuggcccug ucuucuugac gagcauuccu 1380
agggggucuuu ccccucucgc caaaggaaug caaggucugu ugaaugucgu gaaggaagca 1440
guuccucugg aagcuucuug aagacaaaca acgucuguag cgacccuuug caggcagcgg 1500
aaccccccac cuggcgacag gugccucugc ggccaaaagc cacguguaua agauacaccu 1560
gcaaaggcgg cacaacccca gugccacguu gugaguugga uaguuguggga aagagucaaa 1620
uggcucuccu caagcguauu caacaagggg cugaaggaug cccagaaggu accccauugu 1680
augggaucug aucuggggcc ucggugcaca ugcuuuacau guguuuaguc gagguuaaaa 1740
aacgucuagg ccccccgaac cacgggggacg ugguuuuccu uugaaaaaca cgauaauacc 1800
auggaccggg gagauggcagc aucgugcgga ggcgcgguuu ucguaggucu gauacucuug 1860

```
accuugucac cgcacuauaa gcuguuccuc gcuaggcuca uauggugguu acaauauuuu 1920
aucaccaggg ccgaggcaca cuugcaagug uggaucccc ccucaacgu ucggggggc 1980
cgcgaugccg ucauccuccu cacgugcgcg auccaccag agcuaaucuu uaccaucacc 2040
aaaaucuugc ucgccauacu cgguccacuc augguggcucc aggcugguau aaccaaagug 2100
ccguacuucg ugcgcgcaca cgggcucauu cgugcaugca ugcuggugcg gaagguugcu 2160
gggggucauu augccaaau ggcucucaug aaguuggccg cacugacagg uacguacguu 2220
uaugaccauc ucaccccacu gcgggacugg gccacgcgg gccacgaga ccuugcggug 2280
gcaguugagc ccgucgucuu cucugauaug gagaccaagg uuaucaccug ggggggcagac 2340
accgcggcgu gugggggacau caucuuggc cugcccgucu ccgcccgcag ggggagggag 2400
auacaucugg gaccggcaga cagccuugaa gggcagggu ggcgacuccu cgcgccuauu 2460
acggccuacu cccaacagac gcgaggccua cuuggcugca ucaucacuag ccucacaggc 2520
cgggacagga accaggucga gggggaggguc caaguggucu ccaccgcaac acaaucuuuc 2580
cuggcgaccu gcgucaaugg cguguguugg acugucuauc augguggccgg cucaaagacc 2640
cuugccggcc caaagggccc aaucacccaa auguacacca augguggacca ggaccucguc 2700
ggcuggcaag cgccccccgg ggcgcguucc uugacaccau gcaccugcgg cagcucggac 2760
cuuuacuugg ucacgaggca ugccgauguc auuccggugc gccggcgggg cgacagcagg 2820
gggagccuac ucuccccag gcccgucucc uacuugaagg gcucuucggg cgguccacug 2880
cucugccccu cggggcacgc uguggggcauc uuucgggcug ccgugugcac ccgaggggguu 2940
gcgaaggcgg uggacuuugu acccgucgag ucuauggaaa ccacuaugcg gucccggguc 3000
uucacggaca acucguccc uccggccgua ccgcagacau uccagguggc ccaucuacac 3060
gccccuacug guagcggcaa gagcacuaag gugccggcug cguaugcagc ccaaggguau 3120
aaggugcuug uccugaaccc guccgucgcc gccacccuag guuucggggc guauaugucu 3180
aaggcacaug guaucgaccc uaacaucaga accggggguaa ggaccaucac cacgggugcc 3240
cccaucacgu acuccaccua uggcaaguuu cuugccgacg gugguugcuc uggggggcgcc 3300
uaugacauca uaauauguga ugagugccac ucaacugacu cgaccacuau ccugggcauc 3360
ggcacaguc uggaccaagc ggagacggcu ggagcgcgac ucgucgugcu cgccaccgcu 3420
acgccuccgg gaucggucac cgugccacau ccaaacaucg aggaggguggc ucuguccagc 3480
acuggagaaa uccccuuuua uggcaaagcc aucccaucg agaccaucaa gggggggagg 3540
caccucauuu ucugccauuc caagaagaaa ugugaugagc ucgccgcgaa gcuguccggc 3600
cucggacuca augcuguagc auauuaccgg ggccuugaug uauccgucau accaacuagc 3660
ggagacguca uugucguagc aacggacgcu cuaaugacgg gcuuuaccgg cgauuucgac 3720
ucagugaucg acugcaauac auguguacc cagacagucg acuucagccu ggacccgacc 3780
uucaccauug agacgacgac cgugccacaa gacgcggugu cacgcucgca gcggcgaggc 3840
aggacuggua ggggcaggau gggcauuuac agguuuguga cuccaggaga acggcccucg 3900
ggcauguucg auuccucggu ucugugcgag ugcuaugacg cgggcugugc uugguacgag 3960
cucacgcccg ccgagaccuc aguuagguug cgggcuuacc uaaacacacc agggguugccc 4020
gucugccagg accaucugga guucugggag agcgucuuua caggccucac ccacauagac 4080
gcccauuucu uguccccagac uaagcaggca ggagacaacu uccccuaccu gguagcauac 4140
caggcuacgg ugugcgccag ggcucaggcu ccaccuccau cguggggacca aauguggaag 4200
ugucucauac ggcuaaagcc uacgcugcac gggccaacgc cccugcugua uaggcuggga 4260
gccguucaaa acgagguuac uaccacacac cccauaacca aauacaucau ggcaugcaug 4320
ucggcugacc uggaggucgu cacgagcacc uggggugcugg uaggcggagu ccuagcagcu 4380
cuggccgcgu auugccugac aacaggcagc gugguccauug ugggcaggau caucuugucc 4440
ggaaagccgg ccaucauucc cgacagggaa guccuuuacc gggaguucga ugagauggaa 4500
gagugcgccu cacaccuccc uuuacaucgaa cagggaaugc agcucgccga acaauucaaa 4560
cagaaggcaa ucggguugcu gcaaacagcc accaagcaag cggaggcugc ugucccgugg 4620
guggaaucca aguggcggac ccucgaagcc uucugggcga agcauaugug gaauuucauc 4680
agcgggauac aauauuuagc aggcuugucc acucugccug gcaaccccgc gauagcauca 4740
cugauggcau ucacagccuc uaucaccagc ccgcucacca cccaacauac ccuccuguuu 4800
aacauccugg ggggaugggu ggccgcccaa cuugcuccuc ccagcgcugc uucugcuuuc 4860
guaggcgccg gcaucgcugg agcggcuguu ggcagcauag gccuugggaa ggugcuugug 4920
gauauuuugg caggguuaugg agcagggggug gcaggcgcgc ucguggccuu uaaggucaug 4980
agcggcgaga ugcccuccac cgaggaccug guuaaccuac ucccugcuau ccucucccu 5040
ggcgcccuag ucgucggggu cgugugcgca gcgauacgcg ucggcacgu gggcccaggg 5100
gaggggggcug ugcaguggau gaaccggcug auagcguucg cuucgcgggg uaaccacguc 5160
```

                                          -2-

```
uccccacgc acuaugugcc ugagagcgac gcugcagcac gugucacuca gauccucucu 5220
agucuuacca ucacucagcu gcugaagagg cuucaccagu ggaucaacga ggacugcucc 5280
acgccaugcu ccggcucgug gcuaagagau guuugggauu ggauaugcac ggguuugacu 5340
gauuucaaga ccuggcucca guccaagcuc cugccgcgau ugccgggagu ccccuucuuc 5400
ucaugucaac gugggguacaa gggagucugg cggggcgacg gcaucaugca aaccaccugc 5460
ccauguggag cacagacgug cggacaugug aaaaacgguu ccaugaggau cgugggggccu 5520
aggaccugua guaacacgug gcauggaaca uuccccauua acgcguacac cacgggcccc 5580
ugcacgcccu ccccggcgcc aaauuauucu agggcgcugu ggcgggugc ugcugaggag 5640
uacguggagg uuacgcgggu gggggauuuc cacuacguga cgggcaugac cacugacaac 5700
guaaagugcc cgugucaggu uccggcaaccc cuccuacggg aggagguac auuccugguc 5760
uugcacaggu acgcuccagc gugcaaaccag cucccaugcg agcccgaacc ggacguagca 5820
gugcucacuu ccaugcucac cgaccccucc cacauuacgg cggagacggc uaagcguagg 5880
cuggccaggg gaucuccccc cuccuuggcc agcucaucag cuauccagcu gucugcgccu 5940
uccuugaagg caacaugcac uacccgucau gacuccccgg acgcugaccu caucgaggcc 6000
aaccuccugu ggcggcagga gaugggcggg aacaucaccc gcguggaguc agaaaauaag 6060
guaguaauuu uggacucuuu cgagccgcuc caagcggagg aggaugagag ggaaguaucc 6120
guuccggcgg agauccugcg gaggccaggg aaauucccuc gagcgaugcc cauaugggca 6180
cgcccggauu acaaacccucc acguuagag uccuggaagg accccggacua cguccccucca 6240
gugguacacg ggguguccauu gccgccugcc aaggcccuc cgauaccacc uccacggagg 6300
aagaggacgg uuguccuguc agaaucuacc gugucuucug ccuuggcgga gcucgccaca 6360
aagaccuucg gcagcuccga aucgucggcc gucgacagcg gcacggcaac ggccucuccu 6420
gaccagcccu ccgacgacgg cgacgcggga uccgacguug agucguacuc cuccaugccc 6480
ccccuugagg gggagccggg ggaucccgau cucagcgacg ggucuugguc uaccguaagc 6540
gaggaggcua gugaggacgu cgucugcugc ucgauguccu acacauggac aggcgcccug 6600
aucacgccau gcgcugcgga ggaaaccaag cugcccauca augcacugag caacucuuug 6660
cuccgucacc acaacuuggu cuaugcuaca acaucucgca gcgcaagccu gcggcagaag 6720
aaggucaccu uugacagacu gcagguccug gacgaccacu accgggacgu gcucaaggag 6780
augaaggcga aggcguccac aguuaaggcu aaacuucuau ccguggagga agccuguaag 6840
cugacgcccc cacauucggc cagaucuaaa uuuggcuaug gggcaaagga cguccggaac 6900
cuauccagca aggccguuaa ccacauccgc uccgugugga aggacuugcu ggaagacacu 6960
gagacaccaa uugacaccac caucauggca aaaaaugagg uuuucugcgu ccaaccagag 7020
aaggggggcc gcaagccagc ucgccuuauc guauuccccag auuuggggggu ucgugugugc 7080
gagaaaaugg cccuuuacga uguggucucc acccucccuc aggccgugau gggcucuuca 7140
uacggauucc aauacucucc uggacagcgg gucgaguucc uggugaaugc cuggaaagcg 7200
aagaaaugcc cuaugggcuu cgcauaugac acccgcguuu uugacucaac ggucacugag 7260
aaugacaucc guguugagga gucaaucuac caauguugug acuuggcccc cgaagccaga 7320
caggccauaa ggucgcucac agagcggcuu uacaucgggg gcccccugac uaauucuaaa 7380
gggcagaacu gcggcuaucg ccggugccgc gcgagcggug uacugacgac cagcugcggu 7440
aauacccuca cauguuacuu gaaggccgcu gcggccuguc gagcugcgaa gcuccaggac 7500
ugcacgaugc ucguaugcgg agacgaccuu gucguuaucu gugaaagcgc ggggacccaa 7560
gaggacgagg cgagccuacg ggccuucacg gaggcuauga cuagauacuc ugccccccccu 7620
ggggacccgc ccaaaccaga auacgacuug gaguugauaa caucaugcuc cuccaaugug 7680
ucagucgcgc acgaugcauc uggcaaaagg guguacuauc ucacccguga ccccaccacc 7740
ccccuugcgc gggcugcgug ggagacagcu agacacacuc cagucaauuc cuggcuaggc 7800
aacaucauca uguaugcgcc caccuugugg gcaaggauga uccugaugac ucauuucuuc 7860
uccauccuuc uagcucagga caacuugaa aaagcccuag auugucagau cuacggggcc 7920
uguuacucca uugagccacu ugaccuaccu cagaucauuc aacgacucca uggccuuagc 7980
gcauuuucac uccauaguua cucuccaggu gagaucaaua ggguggcuuc augccucagg 8040
aaacuugggg uaccgcccuu gcgagucugg agacaucggg ccagaagugu ccgcgcuagg 8100
cuacuguccc agggggggag ggcugccacu uguggcaagu accucuucaa cugggcagua 8160
aggaccaagc ucaaacucac uccaauccccg gcugcguccc aguuggauuu auccagcugg 8220
uucguugcug guuacagcgg gggagacaua uaucacagcc ugucucgugc ccgaccccgc 8280
ugguucaugu ggugccuacu ccuacuuucu guagggguag gcaucuaucu acuccccaau 8340
cgaugaaggu uggggguaaac acuccggccu cuuaggccau uuccucucuu uuuuuuguuu 8400
```
```
                                                                    8460
```

```
uuuugggouuu uuuuguuuuu uuucuuuuuu uuuuuuuuuu uuucuuuuu ccuucuuccu 8520
uuucucuuuu uuucuucuuu aauggouggcu ccaucuuagc ccuagucacg gcuagcugug 8580
aaaggoccgu gagccgcaug acugcagaga gugcugauac uggccucucu gcagaucaug 8640
ugggocggca uggcaucucc accuccucgc ggouccgaccu gggcauccga aggaggacgu 8700
cgoccacucg gauggcuaag ggagagcucu ag                               8732
```

<210> 2
<211> 8085
<212> DNA
<213> Artificial Sequence

<220>
<223> HCV replicon

<400> 2
```
gccagccccc gattgggggc gacactccac catagatcac tcccctgtga ggaactactg 60
tcttcacgca gaaagcgtct agccatggcg ttagtatgag tgtcgtgcag cctccaggac 120
ccccccctccc gggagagcca tagtggtctg cggaaccggt gagtacaccg gaattgccag 180
gacgaccggg tcctttcttg gatcaacccg ctcaatgcct ggagatttgg gcgtgccccc 240
gcgagactgc tagccgagta gtgttgggtc gcgaaaggcc ttgtggtact gcctgatagg 300
gtgcttgcga gtgccccggg aggtctcgta gaccgtgcac catgagcacg aatcctaaac 360
ctcaaagaaa aaccaaaggg cgcgccatgc acccagaaac gctggtgaaa gtaaaagatg 420
ctgaagatca gttgggtgca cgagtgggtt acatcgaact ggatctcaac agcggtaaga 480
tccttgagag ttttcgcccc gaagaacgtt ttccaatgat gagcactttt aaagttctgc 540
tatgtggcgc ggtattatcc cgtattgacg ccgggcaaga gcaactcggt cgccgcatac 600
actattctca gaatgacttg gttgagtact caccagtcac agaaaagcat cttacggatg 660
gcatgacagt aagagaatta tgcagtgctg ccataaccat gagtgataac actgcggcca 720
acttacttct gacaacgatc ggaggaccga aggagctaac cgcttttttg cacaacatgg 780
gggatcatgt aactcgcctt gatcgttggg aaccggagct gaatgaagcc ataccaaacg 840
acgagcgtga caccacgatg cctgtagcaa tggcaacaac gttgcgcaaa ctattaactg 900
gcgaactact tactctagct tcccggcaac aattaataga ctggatggag gcggataaag 960
ttgcaggacc acttctgcgc tcggcccttc cggctggctg gtttattgct gataaatctg 1020
gagccggtga gcgtgggtct cgcggtatca ttgcagcact ggggccagat ggtaagccct 1080
cccgtatcgt agttatctac acgacgggga gtcaggcaac tatggatgaa cgaaatagac 1140
agatcgctga gataggtgcc tcactgatta agcattggta agtttaaaca gaccacaacg 1200
gtttccctct agcgggatca attccgcccc tctccctccc ccccccctaa cgttactggc 1260
cgaagccgct tggaataagg ccggtgtgcg tttgtctata tgttattttc caccatattg 1320
ccgtcttttg gcaatgtgag ggcccggaaa cctggccctg tcttcttgac gagcattcct 1380
aggggtcttt cccctctcgc caaaggaatg caaggtctgt tgaatgtcgt gaaggaagca 1440
gttcctctgg aagcttcttg aagacaaaca acgtctgtag cgacccctttg caggcagcgg 1500
aaccccccac ctggcgacag gtgcctctgc ggccaaaagc cacgtgtata agatacacct 1560
gcaaaggcgg cacaacccca gtgccacgtt gtgagttgga tagttgtgga aagagtcaaa 1620
tggctctcct caagcgtatt caacaagggg ctgaaggatg cccagaaggt accccattgt 1680
atgggatctg atctggggcc tcggtgcaca tgctttacat gtgtttagtc gaggttaaaa 1740
aacgtctagg ccccccgaac cacggggacg tggttttcct ttgaaaaaca cgataatacc 1800
atggcgccta ttacggccta ctcccaacag acgcgaggcc tacttggctg catcatcact 1860
agcctcacag gccgggacag gaaccaggtc gagggggagg tccaagtggt ctccaccgca 1920
acacaatctt tcctggcgac ctgcgtcaat ggcgtgtgtt ggactgtcta tcatggtgcc 1980
ggctcaaaga cccttgccgg cccaaagggc ccaatcaccc aaatgtacac caatgtggac 2040
caggacctcg tcggctggca gcgccccccc ggggcgcgtt ccttgacacc atgcacctgc 2100
ggcagctcgg acctttactt ggtcacgagg catgccgatg tcattccggt gcgccggcgg 2160
ggcgacagca gggggagcct actctccccc aggcccgtct cctacttgaa gggctcttcg 2220
ggcggtccac tgctctgccc ctcggggcac gctgtgggca tctttcgggc tgccgtgtgc 2280
```

                                    -4-

```
acccgagggg ttgcgaaggc ggtggacttt gtacccgtcg agtctatgga aaccactatg 2340
cggtccccgg tcttcacgga caactcgtcc cctccggccg taccgcagac attccaggtg 2400
gcccatctac acgcccctac tggtagcggc aagagcacta aggtgccggc tgcgtatgca 2460
gcccaagggt ataaggtgct tgtcctgaac ccgtccgtcg ccgccaccct aggtttcggg 2520
gcgtatatgt ctaaggcaca tggtatcgac cctaacatca gaaccggggt aaggaccatc 2580
accacgggtg cccccatcac gtactccacc tatggcaagt ttcttgccga cggtggttgc 2640
tctgggggcg cctatgacat cataatatgt gatgagtgcc actcaactga ctcgaccact 2700
atcctgggca tcggcacagt cctggaccaa gcggagacgg ctggagcgcg actcgtcgtg 2760
ctcgccaccg ctacgcctcc gggatcggtc accgtgccac atccaaacat cgaggaggtg 2820
gctctgtcca gcactggaga aatccccttt tatggcaaag ccatccccat cgagaccatc 2880
aagggggggga ggcacctcat tttctgccat tccaagaaga aatgtgatga gctcgccgcg 2940
aagctgtccg gcctcggact caatgctgta gcatattacc gggggccttga tgtatccgtc 3000
ataccaacta gcggagacgt cattgtcgta gcaacggacg ctctaatgac gggctttacc 3060
ggcgatttcg actcagtgat cgactgcaat acatgtgtca cccagacagt cgacttcagc 3120
ctggacccga ccttcaccat tgagacgacg accgtgccac aagacgcggt gtcacgctcg 3180
cagcggcgag gcaggactgg tagggggcagg atgggcattt acaggtttgt gactccagga 3240
gaacggccct cgggcatgtt cgattcctcg gttctgtgcg agtgctatga cgcgggctgt 3300
gcttggtacg agctcacgcc cgccgagacc tcagttaggt tgcgggctta cctaaacaca 3360
ccagggttgc ccgtctgcca ggaccatctg gagttctggg agagcgtctt tacaggcctc 3420
acccacatag acgcccattt cttgtcccag actaagcagg caggagacaa cttcccctac 3480
ctggtagcat accaggctac ggtgtgcgcc agggctcagg ctccacctcc atcgtgggac 3540
caaatgtgga agtgtctcat acggctaaag cctacgctgc acgggccaac gccctgctg 3600
tataggctgg gagccgttca aaacgaggtt actaccacac accccataac caaatacatc 3660
atggcatgca tgtcggctga cctggaggtc gtcacgagca cctgggtgct ggtaggcgga 3720
gtcctagcag ctctggccgc gtattgcctg acaacaggca gcgtggtcat tgtgggcagg 3780
atcatcttgt ccggaaagcc ggccatcatt cccgacaggg aagtcctttta ccgggagttc 3840
gatgagatgg aagagtgcgc ctcacacctc ccttacatcg aacagggaat gcagctcgcc 3900
gaacaattca aacagaaggc aatcgggttg ctgcaaacag ccaccaagca agcggaggct 3960
gctgctcccg tggtggaatc caagtggcgg accctcgaag ccttctgggc gaagcatatg 4020
tggaatttca tcagcgggat acaatattta gcaggcttgt ccactctgcc tggcaacccc 4080
gcgatagcat cactgatggc attcacagcc tctatcacca gcccgctcac cacccaacat 4140
accctcctgt ttaacatcct gggggggatgg gtggccgccc aacttgctcc tcccagcgct 4200
gcttctgctt tcgtaggcgc cggcatcgct ggagcggctg ttggcagcat aggccttggg 4260
aaggtgcttg tggatatttt ggcaggttat ggagcagggg tggcaggcgc gctcgtggcc 4320
tttaaggtca tgagcggcga gatgccctcc accgaggacc tggttaacct actccctgct 4380
atcctctccc ctggcgccct agtcgtcggg gtcgtgtgcg cagcgatact gcgtcggcac 4440
gtgggcccag gggagggggc tgtgcagtgg atgaaccggc tgatagcgtt cgcttcgcgg 4500
ggtaaccacg tctcccccac gcactatgtg cctgagagcg acgctgcagc acgtgtcact 4560
cagatcctct ctagtcttac catcactcag ctgctgaaga ggcttcacca gtggatcaac 4620
gaggactgct ccacgccatg ctccggctcg tggctaagag atgtttggga ttggatatgc 4680
acggtgttga ctgatttcaa gacctggctc cagtccaagc tcctgccgcg attgccggga 4740
gtccccttct tctcatgtca acgtgggtac aagggagtct ggcggggcga cggcatcatg 4800
caaaccacct gcccatgtgg agcacagatc accggacatg tgaaaaacgg ttccatgagg 4860
atcgtgggggc ctaggacctg tagtaacacg tggcatggaa cattccccat taacgcgtac 4920
accacgggcc cctgcacgcc ctccccggcg ccaaattatt ctagggcgct gtggcgggtg 4980
gctgctgagg agtacgtgga ggttacgcgg gtgggggatt tccactacgt gacgggcatg 5040
accactgaca acgtaaagtg cccgtgtcag gttccggccc ccgaattctt cacagaagtg 5100
gatggggtgc ggttgcacag gtacgctcca gcgtgcaaac ccctcctacg ggaggaggtc 5160
acattcctgg tcgggctcaa tcaatacctg gttgggtcac agctcccatg cgagcccgaa 5220
ccggacgtag cagtgctcac ttccatgctc accgacccct cccacattac ggcggagacg 5280
gctaagcgta ggctggccag gggatctccc cctccttgg ccagctcatc agctgcccag 5340
ctgtctgcgc cttccttgaa ggcaacatgc actacccgtc atgactcccc ggacgctgac 5400
ctcatcgagg ccaacctcct gtggcggcag gagatgggcg gaacatcac ccgcgtggag 5460
tcagaaaata aggtagtaat tttggactct ttcgagccgc tccaagcgga ggaggatgag 5520
agggaagtat ccgttccggc ggagatcctg cggaggtcca ggaaattccc tcgagcgatg 5580
```

```
cccatatggg cacgcccgga ttacaaccct ccactgttag agtcctggaa ggacccggac 5640
tacgtccctc cagtggtaca cgggtgtcca ttgccgcctg ccaaggcccc tccgatacca 5700
cctccacgga ggaagaggac ggttgtcctg tcagaatcta ccgtgtcttc tgccttggcg 5760
gagctcgcca caaagacctt cggcagctcc gaatcgtcgg ccgtcgacag cggcacggca 5820
acggcctctc ctgaccagcc ctccgacgac ggcgacgcgg gatccgacgt tgagtcgtac 5880
tcctccatgc ccccccttga gggggaaccg ggggacccgg atctcagtga cgggtcttgg 5940
tctaccgtga gcgaggaagc tagtgaggat gtcgtctgct gctcaatgtc gtatacatgg 6000
acaggcgcct tgatcacgcc atgcgctgcg gaggaaagca agctgcccat caacgcgttg 6060
agcaactctt tgctgcgcca ccataacatg gtttatgcca caacatctcg cagcgcaggc 6120
ctgcggcaga agaaggtcac ctttgacaga ctgcaagtcc tggacgacca ctaccgggac 6180
gtgctcaagg agatgaaggc gaaggcgtcc acagttaagg ctaaactcct atccgtagag 6240
gaagcctgca agctgacgcc cccacattcg gccaaatcca agtttggcta tggggcaaag 6300
gacgtccgga acctatccag caaggccgtt aaccacatcc actccgtgtg gaaggacttg 6360
ctggaagaca ctgtgacacc aattgacacc accatcatgg caaaaaatga ggttttctgt 6420
gtccaaccag agaaaggagg ccgtaagcca gcccgcctta tcgtattccc agatctggga 6480
gtccgtgtat gcgagaagat ggccctctat gatgtggtct ccacccttcc tcaggtcgtg 6540
atgggctcct catacggatt ccagtactct cctgggcagc gagtcgagtt cctggtgaat 6600
acctggaaat caaagaaaaa ccccatgggc ttttcatatg acactcgctg tttcgactca 6660
acggtcaccg agaacgacat ccgtgttgag gagtcaattt accaatgttg tgacttggcc 6720
cccgaagcca gacaggccat aaaatcgctc acagagcggc tttatatcgg gggtcctctg 6780
actaattcaa aagggcagaa ctgcggttat cgccggtgcc gcgcgagcgg cgtgctgacg 6840
actagctgcg gtaacaccct cacatgttac ttgaaggcct ctgcagcctg tcgagctgcg 6900
aagctccagg actgcacgat gctcgtgaac ggagacgacc ttgtcgttat ctgtgaaagc 6960
gcgggaaccc aagaggacgc ggcgagccta cgagtcttca cggaggctat gactaggtac 7020
tctgcccccc ccggggaccc gccccaacca gaatacgact tggagctgat aacatcatgt 7080
tcctccaatg tgtcggtcgc ccacgatgca tcaggcaaaa gggtgtacta cctcacccgt 7140
gatcccacca ccccctcgc acgggctgcg tgggaaacag ctagacacac tccagttaac 7200
tcctggctag caacattat catgtatgcg cccactttgt gggcaaggat gattctgatg 7260
actcacttct tctccatcct tctagcacag gagcaacttg aaaaagccct ggactgccag 7320
atctacgggg cctgttactc cattgagcca cttgacctac ctcagatcat tgaacgactc 7380
catggcctta gcgcattttc actccatagt tactctccag gtgagatcaa tagggtggct 7440
tcatgcctca ggaaacttgg ggtaccgccc ttgcgagctt ggagacaccg gcccggaat 7500
gtccgcgcta ggcttctgtc cagaggaggc agggctgcca tatgtggcaa gtacctcttc 7560
aactgggcag taaggacaaa gcttaaactc actccaatag cggccgctgg ccggctggac 7620
ttgtccagct ggttcacggc tggctacagc gggggagaca tttatcacgg cgtgtctcat 7680
gcccggcccc gctggttctg gttttgccta ctcctgctcg ctgcaggaat aggcatctac 7740
ctcctcccca atcgatgaag gttggggtaa acactccggc ctcttaggcc atttcctctc 7800
ttttttttgt tttttgggt ttttttgttt tttttctttt tttttttttt tttttcttt 7860
ttccttcttc cttttctctt tttttcttct ttaatggtgg ctccatctta gccctagtca 7920
cggctagctg tgaaaggtcc gtgagccgca tgactgcaga gagtgctgat actggcctct 7980
ctgcagatca tgtgggtcgg catggcatct ccacctcctc gcggtccgac ctgggcatcc 8040
gaaggaggac gtcgtccact cggatggcta agggagagct ctaga         8085
```

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US03/12509

A. CLASSIFICATION OF SUBJECT MATTER
IPC(7) : C12Q 1/70; G01N 33/53; C12N 9/00; C07H 21/02, 21/04
US CL : 435/5, 7.9, 183; 536/23.1, 23.2, 23.72

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
    U.S. : 435/5, 7.9, 183; 536/23.1, 23.2, 23.72

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
STN & WEST; Sequence Data bases.

| C. DOCUMENTS CONSIDERED TO BE RELEVANT |

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y,P	US 2002/0142350 A1 (KUKOLJ et al.) 03 October 2002 (03.10.2002), see the entire document, and claim 40.	1-26
Y	US 5,885,779 A (HOUGHTON et al.) 23 March 1999 (23.03.1999), see the entire patent and claims 6-7.	1-26
Y	LOHMANN et al. Mutation in Hepatitis C Virus RNAs Conferring Cell Culture Adaptation. Journal of Virology, February 2001, Vol. 75, No. 3, pages 1437-1449.	1-26
Y	PIETSCHMANN et al. Characterization of Cell Lines Carrying Self-Replicating Hepatitis C Virus RNAs. Journal of Virology, February 2001, Vol. 75, No. 3, pages 1252-1264.	1-26
Y	LOHMANN et al. Replication of Subgenomic Hepatitis C Virus RNAs in a Hepatitis Cell Line. Science, 2 July 1999, Vol. 285, pages 110-113.	1-26

☐ Further documents are listed in the continuation of Box C.   ☐ See patent family annex.

*	Special categories of cited documents:	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A"	document defining the general state of the art which is not considered to be of particular relevance		
"E"	earlier application or patent published on or after the international filing date	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"L"	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"O"	document referring to an oral disclosure, use, exhibition or other means		
"P"	document published prior to the international filing date but later than the priority date claimed	"&"	document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
20 August 2003 (20.08.2003)	24 SEP 2003

Name and mailing address of the ISA/US
    Mail Stop PCT, Attn: ISA/US
    Commissioner for Patents
    P.O. Box 1450
    Alexandria, Virginia 22313-1450
Facsimile No. (703)305-3230
	Authorized officer
	Tekchand Saidha
	
	Telephone No. (703) 308-0196

Form PCT/ISA/210 (second sheet) (July 1998)